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In psychiatry, the Diagnostic and Statistical Manual of Mental Disorders (DSM) is the standard 
classification system used by clinicians to diagnose disorders.  The DSM provides criteria sets 
that are quantifiable and directly observable measures or symptoms associated with each 
disorder.  For classification, a minimum number of criteria must be observed and once this 
threshold is met, a disorder is considered to be present.  For some disorders, a dimensional 
classification is also provided by the DSM where severity of disorder increases as the number of 
criteria observed increases (i.e., None, Mild, Moderate and Severe).  While the criteria sets 
provided by the DSM are the primary assessment mechanisms used by clinicians in psychiatric 
disease classification, some criteria sets may have too many items making them problematic 
and/or inefficient in clinical and research settings.  In addition, psychiatric disorders are 
inherently latent constructs without any direct visual or biological observation available which 
makes validation of psychiatric diagnoses difficult.  The present dissertation proposes and 
applies two empirical statistical methods to address lengthy criteria sets and validation of 
diagnoses. 
The first proposal is a data-driven method packaged as a SAS Macro that systematically 
identifies subsets of criteria and associated cut-offs (i.e., diagnostic short-forms) that yield 
 diagnoses as similar as possible as using the full criteria set.  The motivating example is alcohol 
use disorder (AUD) which is a type of substance use disorder (SUD) in the DSM-5.  A diagnosis 
of AUD is made when two or more of the 11 possible criteria associated with it are observed.  
Relying on data from the National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC-III), the new methodology identifies diagnostic short-forms for AUD by:  (1) 
maximizing the association between the sum scores of all 11 criteria with newly constructed 
subscales from subsets of criteria, (2) optimizing the similarity of AUD prevalence between the 
current DSM-5 rule and newly constructed diagnostic short-forms, (3) maximizing sensitivity 
and specificity of the short-forms against the current DSM-5 rule, and (4) minimizing differences 
in the accuracy of the short-form across chosen covariates.   
The second method introduces external validators of disorder into the process of 
identifying and validating short-forms.  Each step in the first methodology uses some type of 
comparison (i.e., maximizing correlation, sensitivity, specificity) with the current DSM rule 
assuming the DSM is the best diagnostic target to use.  However, the method does not itself 
assess the validity of the criteria-based definition but instead relies on the validity of the original 
diagnosis.  For the second methodology, we no longer assume the validity of the current DSM 
rule and instead introduce the use of external validators (antecedent, concurrent, and predictive) 
as the target when identifying short-forms.  Application of the method is again AUD and the 
NESARC III is used as the data source.  Rather than use the binary yes/no diagnosis, we use the 
dimensional classification framework provided by the DSM to identify and validate subsets and 
associated severity cut-offs (i.e., dimensional short-forms) in a systematic way.  Using each 
external validator separately in the process could prove difficult in determining a consensus 
across the validators.  Instead, our methodology offers a way to combine these external 
 validators into a singular summary measure using factor analysis that derives the external 
composite validator (ECV).  Using NESARC-III and following principles of convergent validity, 
we identify dimensional short-forms that most relate to the ECV in theoretically justified ways.  
Specifically, we obtain nested subsets of the original criteria set that (1) maximize the 
association between ECV and newly constructed subscales from subsets of criteria and (2) obtain 
associated severity cut-offs that maximally discriminate on ECV based on R-Squared.  
Substance use disorders in the DSM-5 include alcohol use disorder (AUD), nicotine use 
disorder (NUD) and drug use disorders (DUDs).  Each of these substances is associated with a 
single underlying SUD construct with the same 11 diagnostic criteria used across each substance 
and the same diagnostic classifications.  Cannabis and non-medical prescription opioids are two 
examples of DUDs and both have recently been identified as major public health priorities.  Due 
to their diagnostic similarity to AUD in the DSM-5, these substances were ideal to also test our 
methodologies.  Using data from the NESARC on criteria for cannabis use disorder (CUD) and 
opioid use disorder (OUD), we forward applied the diagnostic short-forms that accurately 
replicated AUD and also applied the methods to each substance separately.   
Overall, the new methodology was able to identify shorter criteria sets for AUD, CUD, 
and OUD that yielded highly accurate diagnosis compared to the current DSM (i.e., high 
sensitivity and specificity).  Specifically, excluding criteria “Neglected major roles to use” and/or 
“Activities given up to use” created no marked change in ability to diagnose or measure severity 
the same way as DSM-5.  When applying the method for identifying the most valid dimensional 
short-forms using external validators, different severity cut-points compared to the current DSM-
5 were found and different cut-points were found across AUD, OUD, and CUD.  There were 
dimensional short-forms with as few as 7 criteria for AUD, CUD and OUD that demonstrated the 
 same or better level of validity as using all 11 criteria.  We discuss the implications of these 
findings and propose recommendations for future DSM revisions.  Lastly, we review limitations 
and future extensions of each of our proposed methodologies. 
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This dissertation develops two data-driven statistical methodologies for identifying and 
validating shorter symptom criteria sets with direct application to substance use disorder found in 
the Diagnostic and Statistical Manual of Mental Disorders (DSM).  The first method is 
developed in Chapter 1 and systematically identifies subsets of criteria and associated cut-offs 
that yield diagnoses as similar as possible to using the original full-length criteria set in the 
DSM.  The second method, presented in Chapter 2, focuses on assessing validity of shorter 
criteria sets for measuring disorder severity through the use of an empirically derived external 
composite validator.  Both Chapter 1 and 2 use alcohol use disorder criteria as the motivating 
example.  Chapter 3 applies both methods to two other substance use disorders, cannabis and 
non-medical prescription opioids. 
Chapter 1 introduces the problem of lengthy criteria sets in section 1.1 while the rest of 
the section discusses the challenges to constructing short-forms, the current state of 
psychometrics in determining test-shortening methodologies and a brief introduction to our 
proposed methodology to identify short-forms (i.e., diagnostic short-forms).  Section 1.2 
provides information on alcohol use disorder (AUD), the substance in the DSM used to develop 
our methodology.  Section 1.3 details the data source used while the rest of the section details 
each step of our methodological process.  Section 1.4 provides the results of each step outlined in 
the previous section as applied to AUD and assesses method performance.  Section 1.5 discusses 
the overall findings as well as future work and limitations of our method. 
Chapter 2 provides the second methodology for identifying and validating short-forms.  
Section 2.1 introduces the problem of validating latent constructs (i.e., disorders) and how 




an overview of the second method that identifies and validates short-forms (i.e., dimensional 
short-forms) and section 2.3 elaborates on each step through the application of the method to 
AUD.  The rest of the results section provides sensitivity analyses and method performance 
while section 2.4 discusses the overall findings, future work and limitations.   
Chapter 3 applies the short-forms identified in Chapters 1 and 2 using AUD to two new 
disorders, cannabis use disorder (CUD) and opioid use disorder (OUD).  Section 3.2 introduces 
the substances while section 3.3 provides the results of the forward application of both methods 
to CUD and OUD.  In addition, we applied both methods to cannabis users and opioids users 
separately to compare the differences found between forward application compared to the short-
forms identified by applying the algorithms on each substance separately. 
In the conclusion we provide an overview of our proposed methods, a discussion of the 






Identification of Diagnostic Short-Forms 
1.1  INTRODUCTION  
1.1.1 The Diagnostic and Statistical Manual of Mental Disorders 
Diagnostic classifications provide clinicians and researchers a framework for how disorders are 
diagnosed, treated and investigated.  In psychiatry, the current classification system is the 
Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) [American 
Psychiatric Association (APA), 2013].  The DSM-5 provides features called diagnostic criteria 
that are quantifiable and directly observable measures that are associated with each disorder to 
help clinicians diagnose subjects.  Over the years, the DSM has been a valued tool, providing 
clinicians and researchers a standard diagnostic guide used to make assessments.   
Revisions to the DSM have generally followed a lengthy process involving periods of 
major overhaul of the entire manual over multiple years.  These long periods of revision usually 
involve appointing committees or workgroups of experts tasked with making improvements to 
the DSM.  While this approach seems advantageous in facilitating standardized communication 
among users, it has been argued that it prevents the incorporation of new scientific knowledge 
into the manual as it emerges [First, 2016].  With the release of the DSM-5, sponsors describe 
the new guide as a ‘living document’; hoping to break the lengthy revision process of its 
predecessors.  The change from Roman numerals (DSM-II, III, IV) to Arabic (DSM-5) suggests 
a new ‘process paradigm’, which promotes revisions being made in shorter periods of time based 
on incremental advances in scientific knowledge, and/or changes in clinical practice for specified 




recently adopted a continuous improvement model for DSM revisions and has established a new 
DSM web portal (www.dsm5.org) to receive and solicit comments on proposed changes [First, 
2016].  There are five types of substantive proposals that can be submitted: Type 1 proposals 
involve changes to an existing diagnostic criteria set, Type 2 proposals involve the addition of a 
new diagnostic category, Type 3 proposals entail deleting an existing category, Type 4 proposals 
comprise clarifications and corrections and Type 5 proposals involve text changes [First, 2016; 
Moran, 2017].  In this chapter, the focus will be on Type 1 DSM revisions where the primary 
concern is assessing proposed modifications to an existing diagnostic criteria set.  The creation 
of a web portal allows submissions to be made on a continuous basis from interested persons 
(e.g., psychiatric researchers, individual clinicians) or external organizations (e.g., psychiatric 
subspecialty groups, advocacy organizations, APA components) in contrast with the previous 
revision efforts where proposals were drafted by expert committees assigned to the specified 
sections of DSM revisions [First, 2016]. 
1.1.2 Problems that arise with existing criteria sets 
There are at least two circumstances that warrant criteria modifications within the DSM – a 
conceptual problem with the criteria or identification of a superior or simpler way of defining a 
disorder [Zimmerman et al., 2006].  An example of a conceptual problem that was previously 
modified can be seen in the transition from DSM-IV to DSM-5 for substance use disorders 
(SUDs), where two distinct diagnoses for abuse and dependence (in DSM-IV) were combined 
into one substance use disorder (DSM-5).  This change was supported by a large amount of 
empirical evidence including large-scale literature reviews and new data analyses conducted by 




and included over 200,000 study participants in the United States and elsewhere, all indicating a 
single dimensional construct for SUDs [Hasin et al., 2013]. 
While the conceptual problem of DSM-IV’s distinction between substance abuse and 
dependence was eliminated, this integration led to DSM-5 SUDs having 11 criteria, more than 
was previously used in DSM-IV dependence (7 criteria) or abuse (4 criteria).  The problem of 
DSM criteria sets being too lengthy for clinicians and researchers to implement has been 
documented, particularly in major depressive disorder (MDD) with nine criteria [Zimmerman et 
al., 2006].  Even longer lists of criteria discourage clinicians from learning and using them.  For 
example, when general practitioners were asked to list which criteria they used to diagnose 
depression, only one quarter listed at least five of the nine MDD criteria, while even after an 
educational program, only two-thirds indicated they used the formal diagnostic criteria 
[Krupinski and Tiller, 2001; Learman et al., 2003].   
Another potential problem that arises from psychiatric criteria sets that are too lengthy is 
the increased heterogeneity of possible presentations that end up being diagnosed.  Ideally, 
disorders are supposed to be defined by a clear set of criteria that allow clinicians and researchers 
to develop and apply more targeted treatments.  However, as criteria are added in attempts to 
more accurately define disorders, many of the criteria sets become more complicated which can 
lead to individuals with the same diagnoses having remarkably distinct criteria presentations.  
For example, combining the two diagnoses of dependence and abuse into one may have 
simplified overall diagnosis, but in fact it increased the total number of criteria combinations that 
can lead to a diagnosis.  Specifically, DSM-IV’s dependence and abuse taken together had 1,485 
possible combinations of criteria that could result in a diagnosis, which increased in the DSM-5 




disorder (PTSD) where there are 636,120 different ways to have the disorder based on the 
requirement of having a minimum of 8 of 19 possible total criteria in DSM-5 [Galatzer-Levy and 
Bryant, 2013].  Hence, lengthy criteria sets encompass more heterogeneous presentations that 
may limit the field’s ability to target the disorder for research and treatment. 
A related problem that occurs in lengthy criteria sets or scales is redundancy among the 
items.  Investigations of DSM-IV 15-item Geriatric Depression Scales’ (GDS) psychometric 
properties using measurement models, including the Rasch model and differential item 
functioning, suggested that some of the items were inefficient and redundant [Tank et al., 2005].  
Moreover, the authors found that creating abbreviated versions with some of the items removed 
resulted in similar overall performance as the original 15-item GDS and recommended that their 
shortened versions were just as adequate as the original [Tank et al., 2005].  These redundancies 
found within full-length criteria sets or scales have the potential to dilute core features of the 
disorder or psychological construct they are supposed to be defining. 
Despite the fact that each of the aforementioned criteria sets and scales are widely used in 
research, their long length can be problematic, inefficient and impractical for some clinical or 
research purposes.  There is a clear need to develop shorter, more efficient and practical versions 
of established full-length criteria sets and scales. In the present study, we focus specifically on 
developing short-forms of criteria sets that are subsets of an original full-length criteria set or 
scale.  That is, a short-form is not a new alternative set of differently worded criteria or items but 
more simply and practically, an optimally chosen subset of the original ones along with a 






1.1.3 Challenges to constructing short-form alternatives to existing criteria sets 
Even though there are compelling reasons for constructing short-form alternatives, there are 
many challenges. The first involves ensuring that we start with a sufficiently validated original 
full-length criteria set [Smith et al., 2000].  Since no new criteria or items are being introduced 
when constructing short-form alternatives, the short-form is completely dependent on the validity 
of the original full-length version.  A second challenge relates to construct validity which 
broadly refers to the structure or organization of different constructs defining the disorder in 
relation to the indicators being used to measure them by a criteria set or scale.  If a disorder or 
trait is a single theoretical construct (unidimensional) or several distinct but related theoretical 
constructs (multidimensional), the short-form used to measure those constructs should represent 
the same dimensions to have construct validity.  For example, the five-factor model of 
personality comprises five broad personality traits manifested by 30 specific personality facets 
from the Revised NEO Personality Inventory (NEO-PIR) [Digman, 1990; McCrae and Costa, 
1992; Edwards, 2001].  To this point, when constructing valid short-form alternatives for 
personality, the short-forms should tap these five dimensions as the original form did.  On the 
other hand, when a construct or disorder is unidimensional, then all criteria or items used to 
measure it will reflect a single common dimension (e.g. from low to high severity) of the 
disorder.  For example, SUDs have been shown to be a unidimensional construct with the 11 
DSM-5 diagnostic criteria reflecting the single theoretical concept of SUD.  As with many of the 
diagnoses in the DSM, diagnosis of an SUD is based on the count of the number of criteria met 
on a single list of criteria.  A short-form alternative for a SUD would only need to tap this single 




The biggest challenge of short-form construction is deciding how to choose the specific 
items for the short-form.  Common methods used in the literature include: (a) selecting items 
with the highest inter-item correlations (Cronbach’s alpha); (b) selecting items with the highest 
loadings on the common factor(s) underlying the items; (c) selecting a subset of items with the 
highest item-total correlations; (d) selecting items that are the most obvious (based on expert 
opinion) indicators of the construct; or (e) selecting items randomly from the original scale 
[Cortina, 1993; Streiner, 2003; Widaman et al., 2011].  Methods (a), (b) and (c) use empirical 
psychometric summaries of the items basing decisions on which items to choose without 
consideration of sampling variability in those summaries, hence those methods may capitalize on 
chance when derived from any one data set.  Cronbach’s alpha is the most often reported internal 
consistency index [Widaman et al., 2011], however, selection of items for a short-form using 
Cronbach’s alpha can lead to extreme levels of item content overlap, leading to “bloated” 
specific factors that represent pairs of redundant items [Cattel and Tsujioka, 1964; Widaman et 
al., 2011].  While use of expert opinion, method (d), for developing original content for criteria 
and items is crucial to face validity, creating short-forms just based on expert opinion will likely 
not be successful in gaining consensus about the quality of the short-form.  Finally, while 
Method (e) of randomly selecting subsets of criteria or items is an unbiased approach, the goal is 
to identify an optimal short-form alternative made up of the ‘best’ items, not just a random 
sample [Widaman et al., 2011]. 
1.1.4 New methods of test-shortening and curtailment 
The development and investigation into short-form methodology is a substantial subfield of 
psychometrics and has contributed to many advances in test-shortening and curtailment [e.g., 




Finkelman, 2015; Black et al., 2017; Gibbons et al., 2017].  More traditional “static” test-
shortening designs, and the focus of our methodology, require all respondents to receive the 
same full set of items, with short-forms identified from the original full set using a specified 
methodology.  For example, Finkelman et al. (2017) developed a short-form version of the 24-
item Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R).  The 
participants completed the full-length SOAPP-R in addition to Aberrant Drug Behavior Index 
(ABDI) assessments which provides a binary outcome by tapping multiple sources of 
information (i.e., addiction in patients with chronic pain, prescription opioid therapy as assessed 
by the patient’s physician, and whether illicit substances or additional medications were used 
without being prescribed as assessed by a toxicology report).  One candidate short-form was 
developed for each possible test length under 24 items and selection of items was conducted 
using least absolute shrinkage and selection operator (lasso) logistic regression with the result of 
ABDI defined as the outcome.  The researchers then identified an optimal 12-item short-form 
utilizing measures of diagnostic accuracy (i.e., maximize Youden J index among short-forms 
where sensitivity ≥ specificity) [Finkelman et al., 2017].  In this example, short-forms for the 
SOAPP-R are identified that maximize the diagnostic accuracy when compared to a separate 
assessment (ABDI) therefore the researcher cannot claim they found a shorter list of items that 
performed as well as using the full SOAPP-R, but one that performed well compared to ABDI.   
 Additional advances in short-form methodology are an alternative to traditional test-
shortening designs and utilize computerized adaptive testing (CAT) that allows for customizing 
the assessment at the individual level [Lord, 1980].  Test-shortening for computer-based 
assessments includes curtailment and stochastic curtailment, which are sequential analysis 




which additional items cannot or are unlikely to change the respondent’s classification 
[Finkelman et al., 2011, 2012; Gibbons et al., 2017; Smits and Finkelman, 2015].  These CAT 
approaches do not require the assessment of every item but rather a subset of items depending on 
when testing was ceased; meaning individuals can be diagnosed based on different subsets of 
criteria. 
1.1.5 A new method for systematically identifying optimal diagnostic short-forms 
Given potential problems associated with lengthy criteria sets and current advances in test-
shortening, the present study develops an empirically-based method to systematically identify 
short-forms.  We introduce the term “diagnostic short-form” to indicate a short-form set of 
criteria or items in combination with a newly chosen threshold for defining a case from this 
short-form.  The primary goal in constructing diagnostic short-form alternatives is to identify 
those that result in a diagnosis as similar as possible to the original, full-length version.  
Specifically, the diagnostic short-form should produce a diagnosis with similar prevalence to the 
original criteria set and exhibit high diagnostic accuracy, i.e. high sensitivity and specificity.   
In the present study, we propose an empirically driven multi-step process that identifies 
optimal diagnostic short-forms through a user-friendly tool in a systematic way.  This process 
allows clinicians and researchers to provide input at specified steps about preferred goals of the 
diagnostic short-form (e.g., correlation with original criteria set, sensitivity, specificity, 
prevalence).  Our method will search the space of all possible diagnostic short-forms that can be 
created from the original criteria set and narrow down the selection based on specific 
optimization rules at various ‘screening steps’ throughout the process.  Our method will utilize 
re-sampling techniques to identify diagnostic short-forms at each step that are statistically 




multi-step process, a manageable list of optimal diagnostic short-forms will be displayed with 
comparative information for decision making purposes.   
We propose an alternative method for static test shortening and apply it to develop the 
best diagnostic short-forms for Alcohol Use Disorder (AUD) based on data collected on subjects 
who were evaluated on the full set of 11 DSM-5 AUD criteria.  Our methodology can be used for 
other diagnoses and extends for use in other types of scale construction; however, AUD provides 
an ideal working example as it is an established and reliable [APA, 2013; Hasin et al., 2013], 
fixed-length set of unidimensional criteria, and there is receptivity to improvements [Hales et al., 
2014; First, 2016]. 
1.2 MOTIVATING EXAMPLE 
1.2.1 Alcohol Use Disorder (AUD) 
In the DSM-5, there are 11 criteria used to diagnose AUD and the current DSM-5 diagnostic rule 
maintains that if two or more of the possible 11 criteria are met, then an individual is diagnosed 
with AUD (Table 1.1).  The goal of the present study is to develop a method to systematically 
identify subsets of the 11 criteria and associated cut-off rules that will yield diagnosis as similar 
as possible to using all 11 criteria.  We will do this by: (1) maximizing the association between 
the sum scores of all 11 criteria with newly constructed subscales from subsets of criteria, (2) 
optimizing the similarity of AUD prevalence between the current DSM-5 rule and newly 
constructed diagnostic short-forms, (3) maximizing sensitivity and specificity of the newly 
constructed diagnostic short-forms against the current DSM-5 rule, and (4) minimizing any 
differences in the accuracy of the short-form across chosen covariates (i.e. age, sex, race, 




1.2.2 Change from DSM-IV to DSM-5 Substance Use Disorders (SUDs) 
AUD is an example of a substance use disorder (SUD) and Table 1.1 provides detailed 
descriptions of each diagnostic criterion associated with DSM-IV and DSM-5 SUDs.  The order 
of AUD diagnostic criteria presented follows the order listed in the DSM-5 manual [NIAAA, 
2015] and the conceptual domains provide useful groupings [Horvath et al., 2016].  According to 
Godier and Park (2015), impaired control criteria (C1-C4) refer to an individual experiencing a 
strong desire to use alcohol, persistent desire/unsuccessful attempts to cut down or control 
alcohol use, alongside increasing amounts or periods of time spent using alcohol, and a great 
deal of time spent carrying out activities relating to alcohol.  Social impairment criteria (C5-C7) 
refer to continued use resulting in a failure to fulfill major obligations relating to 
work/school/home, a reduction in important social/occupational activities, and 
social/interpersonal problems caused or exacerbated by alcohol use [Godier and Park, 2015].  
Risky use (criteria C8 and C9) refers to recurrent use in situations in which it is physically 
hazardous and continued use despite knowledge of a physical or psychological problem relating 
to alcohol use [Godier and Park, 2015].  Lastly, pharmacological criteria (C10, C11) refer to 
tolerance to and withdrawal from alcohol use [Godier and Park, 2015]. 
Each criterion is dichotomous taking a 0 or 1 value depending on whether an individual 
has experienced the criterion or not.  As seen in Table 1.1, one criterion that was in the DSM-IV 
edition is no longer in the DSM-5 (i.e. legal problems) and one has been added to the DSM-5 
that was not previously in the DSM-IV (i.e. craving).  Table 1.1 also provides information on 
which criteria were used to diagnose substance abuse or substance dependence in the DSM-IV 




The division of substance abuse and dependence in the DSM-IV was guided by the 
concept that one dimension of substance problems was formed by the ‘dependence syndrome’ 
while social and interpersonal consequences of heavy use formed the ‘abuse syndrome’ 
[Rounsaville et al., 1986; Hasin et al., 2013].  Following this conceptual division, dependence 
was diagnosed when three or more of the seven dependence criteria were met and among those 
with no dependence diagnosis, abuse was diagnosed when at least one of the four abuse criteria 
was met [Rounsaville et al., 1986; Hasin et al., 2013].  However, during the revision process in 
the transition from the DSM-IV to DSM-5, investigators found unidimensionality over all 
criteria for abuse and dependence, indicating that dependence and the remaining abuse criteria all 
designate the same underlying.  Furthermore, abuse and dependence criteria were found to 
consistently intermix across the severity spectrum which added to the large body of evidence in 
removing the distinction between abuse and dependence criteria [Hasin et al., 2013].   
1.3  METHODS 
1.3.1 Data source 
To develop empirically a diagnostic short-form derived from existing DSM criteria, a data source 
is needed with reliably measured criteria across all subjects.  Ideally, to maximize 
generalizability the sample population should include subjects ranging from very healthy non-
disordered to mild, moderate and severely disordered.  The sample also must be large enough to 
statistically delineate between different short-form alternatives.  While many factors influence 
the statistical power of the screening steps described below, generally we recommend the margin 
of error for 95% confidence intervals should be small for the proportions (e.g. ± 5%) and 
correlations (± 0.10).  Hence, we recommend samples with at least 300 individuals with disorder 




In the present study, we use a large general population sample, the National 
Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) conducted by the 
National Institute on Alcohol Abuse and Alcoholism (NIAAA) from 2012-2013.  The NESARC-
III is a nationally representative sample of 36,309 non-institutionalized U.S. civilians, 18 years 
or older [Grant et al., 2014, 2015a].  Criteria for AUD were measured using the Alcohol Use 
Disorder and Associated Disabilities Interview Schedule (AUDADIS-5), which has been shown 
to have high reliability and validity [Grant et al., 2015b; Hasin et al., 2015]. 
The analytic sample used comprises those NESARC-III participants who reported having 
at least one drink of an alcoholic beverage within the past year (𝑛 = 25,778).  Among current 
drinkers, 51% were male; the racial breakdown was: 69% White, non-Hispanic; 11% African 
American, non-Hispanic; 2% American Indian/Alaska Native, non-Hispanic; 5% Asian/Native 
Hawaiian/Other Pacific Islander, non-Hispanic; 14% Hispanic, any race.  Table 1.1 lists each of 
the 11 DSM-5 AUD criteria and their prevalence in this sample.  See Appendix A for the specific 
wording of the questions that were used to elicit each criterion.  Approximately 15% of current 
drinkers’ report using larger amounts of alcohol for longer (C1), 13% cannot cut down or control 
their drinking (C2) and 12% describe their drinking as physically hazardous (C8).  Each of the 
rest of the criteria is observed in less than 11% of current drinkers.  Thirty-two percent of current 
drinkers met at least one criterion, and based on the current DSM-5 requirement for two or more 
out of 11 criteria being met, 19.1% (95% CI: 18.5%, 19.7%) had AUD. 
1.3.2 Overview of steps for identifying optimal diagnostic short forms 
The goals of the procedure are to obtain a subset (or multiple subsets) of the original criteria set 
and associated diagnostic cut-offs that (1) maximize the association between the sum score of all 




similarity between the prevalence of diagnosis using the new diagnostic short form and the 
original DSM-5 rule, (3) maximize sensitivity and specificity of the newly constructed diagnostic 
short-forms against the current DSM-5 rule, and (4) minimize any differences in the accuracy of 
the short-form across chosen covariates. 
A flow-chart of the empirical steps to accomplish these goals is shown in Figure 1.1, 
where Steps 1-3 deal with choosing the optimal subset of criteria (i.e., subscale) and Steps 4-8 
focus on determining the optimal threshold.  Within the procedure there are screening steps that 
make comparisons between different short-forms or comparisons to a pre-fixed value.  When 
making comparisons, 95% confidence intervals are derived with non-parametric bootstrapping 
[Efron and Tibshirani, 1986], so that random variability is statistically taken into account when 
making conclusions.  A brief description of the procedure for each step is provided in this section 
and specific details applying the method to DSM-5 AUD are provided in the results section. 
1.3.3 Step 1: Assess unidimensionality of full-length criteria set 
A common diagnostic algorithm structure within DSM-5 is to have a single list of 𝑃 different 
criteria and determine that a person is diagnosed with the disorder if they have at least 𝑀 out of 
those 𝑃 criteria present.  This method of counting 𝑃 criteria implicitly assumes that the 𝑃 items 
represent a unidimensional construct [Bond and Fox, 2007].  Bollen and Lennox (1991) 
demonstrated that when a criteria set can be considered a reflective measure of a unidimensional 
construct, any subsets of those items are essentially interchangeable.  Thus, if the original set of 
criteria are unidimensional, then subscales constructed from the full set are unidimensional.  To 
verify unidimensionality, we consult prior literature as well as examine the eigenvalues obtained 
from tetrachoric correlations of the full-length criteria set using the Kaiser criterion [Nunnally 




mean square error of approximation (RMSEA) ≤ 0.06 and comparative fit index (CFI) ≥ 0.95) 
[Hu and Bentler, 1999]. Dimensionality analyses were conducted in Mplus v7.3. 
We note that if the dimensionality of the full-criteria set is determined to be greater than 
one, this would suggest that the original set of items should be organized into separate sets of 
items corresponding to each dimension.  In the case of DSM-5, this separation of criteria sets 
exists for several disorders (e.g., ADHD, PTSD).  The current proposed method can be applied to 
those criteria used to represent each of the separate dimensions of the disorder. 
1.3.4 Step 2: Form all possible subscales from subsets of full-length criteria set 
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, 𝑤ℎ𝑒𝑟𝑒 𝑝 = 1, … , 𝑃 
different subsets of items.  For every subset of items, we then create corresponding subscales by 
taking the simple sum score of the respective items in the subset for each individual in the 
dataset. 
1.3.5 Step 3: Identify optimal subscales using correlation with full-length criteria set 
Establishing which criteria to be included in a subset is the first step in constructing diagnostic 
short-forms.  To narrow down the list of potential subsets, we first calculate the correlation 




confidence intervals for the correlation.  The basic idea is that subscales which have higher 
correlations with the full-length scale will lead to short-forms more similar to the full-length 
criteria set.  In this step, we identify the top subscales of each size 𝑝 by first ranking them by 
their correlation with the total, then selecting the top ranked ones along with all others that have 
correlation not statistically significantly different from the top ranked ones.  The researcher can 
choose to force the inclusion of the top 𝑘 ranked scales, or even just the top one (i.e. best) and 
the method will then also include any other scales that are not significantly different from those 
top ranked scales.  This ensures the screening method will identify at least some minimal number 
of short-forms for each 𝑝 by providing at least one subset from each where  𝑝 = 1, … , 𝑃 − 1.  
The primary focus at this step is rank order of correlation for each subscale within 𝑝 rather than 
magnitude (i.e. setting a threshold for the correlation to identify optimal subscales).  Different 
types of correlation can be considered (e.g., Pearson, Spearman, and polychoric) but generally do 
not differ in terms of how they rank order subscales. 
1.3.6 Step 4: Form all possible diagnostic short-forms from optimal subscales 
Once optimal subscales have been identified across all 𝑝 where  𝑝 = 1, … , 𝑃 − 1, the next step is 
to introduce the threshold component (𝑚) that allows for the subscales to be cut at a specified 
point to determine whether a diagnosis should be made.  To construct an exhaustive list of all 
possible diagnostic short-forms from the optimal subscales in the previous step, we let 𝑚 vary 
from  𝑚 = 1 𝑡𝑜 𝑝 for each subscale. 
1.3.7 Step 5: Identify optimal diagnostic short-forms using comparative prevalence estimates 
It is important that the subscale from the short-form not only correlate well with the original 
criteria set total score, but that the diagnostic short-form produces a disorder prevalence that is 




prevalence estimates of disorder along with 95% confidence intervals for each of the newly 
constructed diagnostic short-forms.  Prevalence estimates of disorder for each diagnostic short-
form are compared to the current full-length rule (i.e., DSM-5 rule) and those that fall within a 
small percentage point difference of the full-length rule prevalence are identified as optimal and 
chosen to move to subsequent steps.  In our AUD example in the next section, we choose a value 
of  5% around the DSM-5 AUD prevalence (19%) thus allowing the population prevalence of 
AUD from the diagnostic short-form to range between 14%-24%.  This tolerance for difference 
can be directly adjusted depending on the goal of the clinician/researcher. 
1.3.8 Step 6: Identify optimal diagnostic short-forms using sensitivity/specificity 
Taking the DSM-5 diagnosis to be the target, we next examine the sensitivity and specificity of 
each diagnostic short-form (DSF) against that target, i.e., 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 = Pr(𝐷𝑆𝐹 + |𝐷𝑆𝑀5 +), 
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = Pr (𝐷𝑆𝐹 − |𝐷𝑆𝑀5−).  In general, there is a trade-off between sensitivity and 
specificity such that the more sensitive a diagnostic short-form, the higher the rate of false 
positives (i.e., the lower the specificity) and vice versa.  For screening in diagnostic short-forms, 
a Youden’s index (𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 + 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑦 − 1) [Youden, 1950] above a certain cut-off can be 
used and has been described as the most optimal method for short cognitive screening 
instruments [Larner, 2015].  More simply, diagnostic short-forms with both sensitivity and 
specificity estimates higher than a cut-off (e.g., 0.90) can be kept.  Hence, optimal diagnostic 
short-forms will be identified when 95% confidence intervals of estimates of sensitivity and 
specificity both contain values greater than or equal to 0.90.  We reviewed literature on the 
diagnostic accuracy of other alcohol screening tools (i.e., CAGE, TWEAK, AUDIT) to 




value can be adjusted or more weight can be placed on either measure depending on the goals of 
the clinician/researcher. 
1.3.9 Step 7: Identify optimal diagnostic short-forms minimizing differential functioning 
across covariates 
A desirable psychometric property for any measurement tool is that it should not exhibit 
differential test functioning (DTF) [Pae and Park, 2006; Ellis and Raju, 2004].  That is, it should 
not exhibit systematic differences in the way it measures the target construct in different 
subgroups than what is currently being captured by the full-length rule.  In our setting, we are 
concerned with reducing the systematic differences with the entire diagnostic short-form rather 
than with each item within the short-form.  Inherently, there may be systematic differences in the 
way a specified item behaves in certain subgroups (e.g., “Social/interpersonal problems” (C6) 
could depend on cultural differences across races).  However, we are concerned with assessing 
DTF of the entire measure rather than specific item-level DTF, because taken as a whole, these 
item-level differences can cancel each other out. 
 To assess this among the diagnostic short-forms, we perform logistic regression with the 
diagnostic short-form as the outcome predicted by the full-length diagnostic rule (i.e., DSM-5) 
and relevant covariates (e.g., age, sex, race, diagnosis of any mood and/or anxiety disorder).  If 
any covariate is found to be significant in this model, this indicates that the particular diagnostic 
short-form measures the disorder differently across levels of the covariate and hence is less 
desirable since it exhibits DTF.  In this step, our goal is to show that the covariates have a 
minimal effect on the entire diagnostic short-form, above and beyond their effect on the current 




functioning.  The choice of covariates to examine depends on the goals of the 
clinician/researcher based on the relevant subgroups in the population. 
1.3.10 Step 8: Provide final list of optimal diagnostic short-forms and comparative 
information for decision making 
A list of optimal diagnostic short-forms that successfully satisfied the optimization rules at each 
of the four screening steps will be provided.  Estimates and 95% confidence intervals for 
correlation, prevalence, sensitivity and specificity will be provided in the summary table to allow 
the clinician/researcher to make an informed decision as to the ‘best’ diagnostic short-form 
depending on their primary goals.  In addition, figures will be produced to summarize the criteria 
chosen for the optimal diagnostic short-forms. 
1.3.11 Extension of steps to take into account severity cut-offs 
There has been recent movement towards a dimensional approach to psychiatric disorders [Kose 
and Cetin, 2017; Kozak and Cuthbert, 2016] and DSM-5 AUD specifically indicates a severity 
spectrum with four categories: None (0-1 criteria), Mild (2-3 criteria), Moderate (4-5 criteria) 
and Severe (6-11 criteria).  Our new diagnostic short form identification methodology easily 
extends to identify optimal severity measures.  Rather than compare each potential diagnostic 
short-form to the current DSM-5 rule for AUD (2+ criteria), we can re-run our algorithm two 
additional times to obtain the optimal diagnostic short-forms for Moderate AUD (4+ criteria) as 
well as Severe AUD (6+ criteria).  While we recommend diagnostic short-forms falling within 
5% of the current AUD prevalence (Step 5), this may be too lenient when assessing the more 
severe categories that tend to be less prevalent.  In these cases, we recommend not changing the 
prevalence by more than 50% of the current DSM prevalence.  Once the optimal diagnostic 




run of the algorithm and assess the agreement to the current severity dimensions for DSM-5 
AUD. 
1.3.12 Replicability on split halves and on a different data source 
To demonstrate replicability of our results, we (1) re-ran the empirical steps on random split 
halves of the NESARC-III data source and (2) re-ran the empirical steps on a new data source 
(Wave 2 NESARC) and then compared results.  In 2004-2005, approximately three years after 
the initial NESARC (Wave 1), 𝑛 = 34,653 of the Wave 1 participants were re-sampled in Wave 
2 representing a cumulative response rate of 86.7% [Ruan et al., 2007].  Of note, NESARC-III 
was a survey conducted in 2012-2013 on a completely different sample of participants than the 
sample included in NESARC Waves 1 and 2.  We applied our new method to the subsample of 
Wave 2 NESARC participants who reported they were current drinkers (𝑛 = 22,177).  
Participants’ current drinker status was defined in the same manner as in NESARC-III and the 11 
criteria for DSM-5 AUD were measured with only minor differences.  Specifically, “Craving” 
(C4), “Neglected major roles to use” (C5), “Social/interpersonal problems” (C6) and “Hazardous 
use” (C8) each had updates to the survey questions used to elicit each criterion in NESARC-III 
(see Appendix A for survey questions for NESARC-III and Appendix B for survey questions for 
Wave 2 NESARC).  Note that the “Craving” (C4) criterion was not available on the first wave of 
the NESARC, which is why that data source was not also used. 
1.4  RESULTS 
1.4.1 Step 1: Assess unidimensionality 
The DSM-5 AUD criteria set previously has been shown to be unidimensional in Wave 2 




2013] and we found similar results for the NESARC-III sample.  Using the eigenvalues obtained 
from the tetrachoric correlations of all 11 criteria from our sample of 25,778 current drinkers, we 
assessed whether the DSM-5 AUD diagnostic criteria follow a single dimension.  The first 
eigenvalue of the tetrachoric correlation is 8.16 while the rest are < 0.55 and the 1-factor model 
has good model fit by CFI ≥ 0.95 (CFI = 0.998) and RMSEA ≤ 0.06 (RMSEA = 0.013), all 
indicating unidimensionality. 
1.4.2 Step 2: Form all possible subscales 
There are 11 diagnostic criteria associated with DSM-5 AUD resulting in 2,047 possible subsets 
of criteria of varying size, where  𝑝 = 1, … , 11.  Table 1.2 provides a breakdown of the number 
of subsets by size  𝑝.  Once all possible subsets have been enumerated, we take the simple sum 
score of the respective items in each subset and create all possible subscales to be analyzed in the 
next step (Table 1.2, column 2). 
1.4.3 Step 3: Correlation 
In this first screening step, we will narrow down the list of all 2,046 subsets by examining the 
correlation between each subscale (formed by summing the criteria in the subset) and the sum 
score of all 11 AUD criteria.  Figure 1.2 provides the Pearson correlations for all 2,046 subscales 
by the size of the subset, where  𝑝 = 1, … , 11.  The original, full-length criteria set is included in 
Figure 1.2 for reference, where 𝑝 = 11, 𝑐𝑜𝑟𝑟 = 1.00.  As expected, on average, the correlation 
coefficients increase as the number of criteria included in the subset increase.  Nevertheless, 
variability within each set of subscales indicates some subscales with smaller 𝑝 are better than 
others with larger 𝑝. 
In order to ensure all sizes of subsets are represented for subsequent steps, optimal 




correlation and any subscales that are not significantly different from them.  For the present 
AUD example, we take 𝑘 = 1.  Using this method, optimal subscales will be identified for each 
𝑝 by providing at least one subscale from each, where 𝑝 = 1, … , 10.  To illustrate, when 𝑝 = 6 
there are a total of 462 possible subsets that have six criteria (see Table 1.2).  Figure 1.3 provides 
the correlation coefficients for the top 15 subscales of size 𝑝 = 6 with associated 95% 
confidence intervals.  Based on this ranking, there are nine other subscales that have 95% 
confidence intervals overlapping the top ranked one, hence all ten subscales will pass this first 
screening test (see Figure 1.3 red outline identifying the selection of the ten optimal subscales). 
We can also examine the specific criteria being selected in the top subscales.  Continuing 
with our example of top subscales selected of size 𝑝 = 6, Figure 1.4 displays the specific criteria 
that were included.  Each row in the figure indicates whether or not each of the 11 possible 
criteria were included (black boxes) or excluded (gray boxes) in the subscales.  Figure 1.4 allows 
us to gain insight into potential patterns of criteria selection.  For example, we see that “Craving” 
(C4) is included in each of the top 10 subscales size 𝑝 = 6 and “Repeated attempts to 
quit/control” (C2), “Hazardous use” (C8), “Physical/psychological problems” (C9) and 
“Withdrawal” C11 are included in eight of the top subscales. While “Neglected major roles to 
use” (C5) and “Activities given up to use” (C7) are never selected. 
Applying this screening of correlations across all 𝑝, we end up with a total of 86 
subscales that pass this first screening test and will move to subsequent steps.  Table 1.2 provides 
the breakdown of chosen subscales, their corresponding mean correlations with the original, full-
length criteria set and the percent of subscales chosen among the total possible for each 𝑝.  The 
percentages are provided in order to give reference to the number of subscales selected within 𝑝 




we see that there were 23 subscales chosen with size 𝑝 = 4 while there were only two subscales 
chosen with size 𝑝 = 10.  However, since there were 330 subscales possible of size 𝑝 = 4 and 
11 subscales possible of size 𝑝 = 10, optimal subscales selected among total possible was 7.0% 
and 18.2%, respectively.  The primary goal of this first screening step is to narrow the space of 
all possible subscales and we see that among the 2,046 possible subscales, this step identified 
4.2% of subscales to be assessed at subsequent steps in the process.  The correlations between 
the top chosen subscales at each size 𝑝 and the full 11 criteria sum score range from 0.718 to 
0.998 (Table 1.2, column 4). 
1.4.4 Step 4: Form all possible diagnostic short-forms 
Once optimal subscales have been identified, the next step is to incorporate the threshold 
component (𝑚) that allows the sum scores to be cut at specified points in order to make a 
diagnosis.  We let 𝑚 vary from 𝑚 = 1 𝑡𝑜 𝑝 to construct all possible diagnostic short-forms and 
Table 1.2 provides the breakdown of the total number of diagnostic short-forms constructed from 
each optimal subscale across all sizes of 𝑝.  Extending this notion to all 86 subscales, we obtain 
401 diagnostic short-forms that will be assessed in subsequent steps (Table 1.2, column 5). 
1.4.5 Step 5: Prevalence 
We next assess the differences in prevalence of diagnosis between each diagnostic short-form 
and DSM-5 AUD.  Because the prevalence of AUD using the DSM-5 is 19.1% in this sample of 
current drinkers, we implemented a tolerance of  5% as the threshold for difference, although 
this could easily be made smaller or larger.  For a disorder with lower prevalence, a smaller 
tolerance for difference may be desirable.  There were 72 out of the 401 DSFs screened in by 




1.5).  Of note, the optimal diagnostic short-forms with smaller 𝑝 (𝑝 = 1, 2, 3, 4) were found to 
have a threshold of  𝑚 = 1, whereas the larger diagnostic short-forms (𝑝 = 6, 7, 8, 9, 10) had a 
threshold of  𝑚 = 2.  These findings show the impact of maintaining prevalence of disorder at  
5% on the threshold; when fewer criteria are included, the optimal threshold requires fewer 
criteria compared to when more criteria are included. 
1.4.6 Step 6: Sensitivity and Specificity 
Treating DSM-5 AUD as the target diagnosis, the sensitivity and specificity for each of the 72 
diagnostic short-forms was calculated.  The primary goal at this screening step was to identify 
diagnostic short-forms that optimize these measures in terms of increasing true positive rate 
(sensitivity) while decreasing the false positive rate (1-specificity).  Figure 1.6 provides the 
sensitivity and 1-specificity of each of the 72 diagnostic short-forms with 95% confidence 
intervals around the sensitivity.  In this figure, there are two clusters of diagnostic short-forms.  
The first cluster lies along the y-axis with 1-specificity of 0.00 and sensitivity ranging from 0.70 
to 1.00 indicating that there are no false positives but the true positive rate varies depending on 
which diagnostic short-form is being used.  This cluster of diagnostic short-forms all have a 
threshold of 𝑚 = 2 and since they are being compared to the DSM-5 rule which also has a 
threshold of 𝑚 = 2, they cannot identify any disorders that the DSM-5 AUD rule did not already 
identify resulting in no false positives.  The second cluster arcs slightly along the x-axis with 1-
specificity ranging from 0.02 to 0.09 and sensitivity ranging from 0.65 to 0.95.  Each of these 
diagnostic short-forms only requires a single criterion to be met in order to make a diagnosis 
(𝑚 = 1) making them more ‘lenient’ rules which is why they have non-zero false positive rate 




In order to identify optimal diagnostic short-forms at this screening step, we choose those 
that maximize the true positive rate and minimize the false positive rate.  These optimal points of 
interest cluster in the top left corner of Figure 1.6.  Using 0.90 as the cutoff value for optimizing 
both sensitivity and specificity (≤ 0.1 cutoff for 1-specificity), there are 25 diagnostic short-
forms identified with their 95% confidence interval containing this cutoff value and can be seen 
in Figure 1.6 outlined in red. 
1.4.7 Step 7: Differential Test Functioning (DTF) 
The distribution of the covariates examined in relation to differential test functioning were: age 
(52.0% of sample < 45 years old), sex (50.7% Male), race/ethnicity (80.8% White, Hispanic/non-
Hispanic), and diagnosis of any mood and/or anxiety disorder (22.3%, with rule out on 
substance-induced).  Among the 25 optimal diagnostic short-forms considered at this step, four 
were highly accurate (i.e., with sensitivity >97% and specificity = 100%) with 𝑝 = 8, 9 and 10 
and were bypassed from explicit testing as there was quasi- or complete separation in the logistic 
model due to there being no variability left between the diagnostic short-form and the DSM-5 to 
be explained by covariates.  Of the remaining 21 optimal diagnostic short forms, there were 14 
with 𝑝 = 4 criteria, only two of which did not have any differential functioning across levels of 
the specified covariates (see Table 1.3).  Of the three 𝑝 = 5 and single 𝑝 = 6 diagnostic short-
forms, none screened past this step, as they all exhibited differential functioning by age and/or 
any mood/anxiety disorder.  One of the two 𝑝 = 7 diagnostic short-forms and one 𝑝 = 8 
diagnostic short-form was found not to exhibit any differential functioning.  Hence in total, 8 of 





1.4.8 Step 8: Final list of optimal diagnostic short-forms 
The final eight optimal diagnostic short-forms are shown in Figure 1.7 and the associated 
descriptive statistics (i.e., correlations, prevalence, sensitivity, specificity) in Table 1.4 and 
Figure 1.8.  Optimal rules were found for size 𝑝 = 4, 7, 8, 9 and 10 out of the 11 original criteria, 
with threshold of 𝑚 = 1 for the 𝑝 = 4  rule, and 𝑚 = 2 for the rest.  Nearly perfect sensitivity 
and specificity were found for the 𝑝 = 8, 9, and 10 rules, with a 𝑝 = 4 rule that reached 92% 
sensitivity and specificity.  Among the diagnostic short-forms identified for DSM-5 AUD using 
NESARC-III, “Neglected major roles to use” (C5) and “Activities given up to use” (C7) are the 
first two criteria to be excluded.  “Used larger amounts/longer” (C1), “Repeated attempts to 
quit/control” (C2), “Craving” (C4), “Hazardous use” (C8), “Physical/psychological problems” 
(C9), “Tolerance” (C10) and “Withdrawal” (C11) are consistently included in the optimal 
diagnostic short-forms, which may indicate their primary importance to the diagnosis of AUD. 
1.4.9 Step 8: Diagnostic short-forms for AUD severity 
When the methodology was re-run using Moderate (4+) and Severe (6+) DSM-5 diagnosis as the 
targets, the same 𝑝 = 9 subscale that excluded both “Neglected major roles to use” (C5) and 
“Activities given up to use” (C7) was consistently identified as optimal.  Based on only these 
nine criteria, the optimal threshold for Moderate and Severe were found to be 4+ and 5+ criteria, 
respectively.  Table 1.5 provides the concordance of the NESARC-III participants in each AUD 
Severity group using the DSM-5 AUD Severity rule compared to the optimal one, with 𝑝 =
9 corresponding to DSF 89.  The agreement has a weighted 𝐾𝑎𝑝𝑝𝑎 = 0.97, which indicates an 
almost perfect level of agreement [Viera and Garrett, 2005].  Furthermore, there are only 2% 
misclassified participants, most being persons who were Moderate according to DSM-5 




extended to identify diagnostic short-forms that perform well not just for diagnosis but also for 
disorder severity. 
1.4.10 Demonstrating performance of method on random split halves 
A split-half technique was used for checking the reproducibility of the optimal diagnostic short-
forms.  Using simple random sampling, we split the NESARC-III data into two datasets: Split 
half 1 (𝑛 = 12,889) and Split half 2 (𝑛 = 12,889) (Table 1.6).  We then proceeded to apply the 
new method to identify optimal diagnostic short-forms in each split half in order to compare if 
the same results emerged.   
Figure 1.9 presents the optimal diagnostic short-forms identified in both split halves of 
the data.  There was a total of 36 unique diagnostic short-forms across the two split halves, 11 
(31%) of which were found in both.  There was 70% overlap when we considered rules 
identified with 𝑝 ≥ 7 compared to only 15% when 𝑝 < 7.  This suggests that reproducibility of 
optimal diagnostic short-forms with larger 𝑝 is higher than those with smaller 𝑝.   
Among the eight optimal diagnostic short-forms identified when using the full NESARC-
III data, all eight (100%) were identified in the split half datasets.  Additionally, if we compare 
the criteria being included/excluded in the split halve datasets, we find the same patterns when 
using the full data.  More specifically, “Used larger amounts/longer” (C1), “Repeated attempts to 
quit/control” (C2), “Craving” (C4), “Hazardous use” (C8), “Physical/psychological problems” 
(C9), “Tolerance” (C10) and “Withdrawal” (C11) are consistently being included while 
“Neglected major roles to use” (C5) and “Activities given up to use” (C7) are consistently being 
excluded.  This is the same pattern of criteria inclusion/exclusion that we were finding when 





1.4.11 Demonstrating performance of method on Wave 2 NESARC 
Applying our algorithm to Wave 2 NESARC, we identified 16 optimal diagnostic short-forms 
for DSM-5 AUD.  Table 1.7 provides the fit statistics and Figure 1.10 provides the criteria 
selected for each of these optimal diagnostic short-forms.  Among the diagnostic short-forms 
identified for DSM-5 AUD using Wave 2 NESARC, “Neglected major roles to use” (C5) and 
“Activities given up to use” (C7) are the first two criteria to be excluded.  While “Used larger 
amounts/longer” (C1), “Repeated attempts to quit/control” (C2), “Hazardous use” (C8), 
“Tolerance” (C10) and “Withdrawal” (C11) are consistently being included in the top 
performers.  These patterns of criteria being included/excluded in the optimal diagnostic short-
forms are consistent with our findings using NESARC-III.   
 Furthermore, the same optimal diagnostic short-forms are being identified in Wave 2 
NESARC that were identified in NESARC-III when eight or more criteria are included (𝑝 ≥ 8).  
More specifically, when 𝑝 = 10, DSF 74 and DSF 26 are identified with a threshold of two and 
exclude either “Neglected major roles to use” (C5) or “Activities given up to use” (C7).  While 
when 𝑝 = 9, DSF 89 is identified with a threshold of two and excludes both of these criteria (C5 
and C7).  For 𝑝 = 8, DSF 120 and DSF 344 are identified as the top performers with a threshold 
of two while excluding both C5 and C7.  Additionally, these diagnostic short-forms chose either 
“Much time spent using” (C3) or “Social/interpersonal problems” (C6) as the third criterion to be 
dropped. 
 These five diagnostic short-forms identified across both sets of data also performed very 
well when compared to the current rule for DSM-5 AUD.  The fit statistics for these top 
performers using NESARC-III and Wave 2 NESARC were consistently high with ≥ 0.987 




minimum, these findings indicate that “Neglected major roles to use” (C5) and “Activities given 
up to use” (C7) may not be of primary importance in the diagnosis of AUD.  We have now found 
in two separate data sources that the performance of a short-form with both of these criteria 
excluded maintains very high diagnostic accuracy measures when compared to the current rule 
with the criteria included. 
1.5 DISCUSSION 
Our data-driven method searches the space of all possible diagnostic short-forms for a particular 
DSM disorder and narrows down the selection based on specific optimization steps to identify 
those that are as similar as possible as the current rule.  The method has been programmed as a 
SAS Macro (Appendix E) that can be applied to any dataset with any set of criteria.  In our 
application to DSM-5 AUD using NESARC-III, there were more than 11,000 possible diagnostic 
short-forms that could be created from the 11 criteria; using our method we were able to narrow 
the possible choices down to eight.  Moreover, the same diagnostic short forms were found with 
8, 9, and 10 criteria when the method was applied to Wave 2 of the NESARC and in split halves 
of the NESARC-III, demonstrating strong replicability of the method and findings.   
Our primary finding for AUD is that excluding “Neglected major roles to use” (C5) 
and/or “Activities given up to use” (C7) created no marked change in ability of these diagnostic 
short-forms to diagnose AUD or indicate its severity when compared to the current DSM-5 
severity criteria (𝑘𝑎𝑝𝑝𝑎 = 0.97).  Further, our method was able to identify two diagnostic short-
forms for AUD with only four criteria (𝑝 = 4) and a threshold of one (𝑚 = 1) that performed 
very well, with prevalence estimates near that of DSM-5 AUD (21% and 25% vs. 19.1%), 
correlations above 0.90 with the total sum score using all 11 criteria, and measures of sensitivity 




 The final selection of optimal diagnostic short-forms is contingent upon optimization 
parameters fixed within the steps that can be adjusted depending on the goal of the user.  These 
decisions will affect the number of diagnostic short-forms that make it to the subsequent steps in 
the algorithm.  For example, we accept those diagnostic short-forms that yield prevalence in the 
sample within 5% of the DSM-5 AUD diagnosis prevalence.  Depending on the importance of 
maintaining current prevalence, this range can be adjusted to be more liberal or conservative in 
terms of how many diagnostic short-forms are selected to move to the next step.  We consider 
this flexibility to be a strength of the methodology and would argue that for the purpose of 
making recommendations for changes to the DSM-5, specific standards could be set by a 
governing body.  A limitation for one of the optimization steps is that the current algorithm only 
allows binary covariates for Step 7 (DTF).  We used a median split to dichotomize continuous 
age, which is the most common method for dichotomization [MacCallum et al., 2002].  
However, since there are drawbacks to dichotomizing continuous variables, we will update our 
macro in future revisions to allow for any form of a covariate to be used for this step. 
 The correlation step (Step 3) is the first screening step to narrow down the possible 
subscales that end up being assessed as diagnostic short-forms in later steps.  Since we found 
five optimal dimensional short-forms of size 𝑝 = 8, 9, 10 at the end of our algorithm, we tested 
whether we would find other more accurate diagnostic short-forms if we opened up the 
correlation step to let through all possible 𝑝 = 8, 9, 10 subscales.  Among the 253 unique 
subscales of these sizes, the algorithm constructed 1,925 diagnostic short-forms to be assessed 
and found that the prevalence and sensitivity/specificity steps reduced the possible choices down 
to 24.  Furthermore, after the last screening step for differential test functioning, there were no 




originally.  This provides evidence that the correlation step is adequately screening out inferior 
subscales that would end up with underperforming diagnostic short-forms in later steps. 
The current DSM-5 rule for AUD uses the sum score of all 11 diagnostic criteria; an 
AUD diagnosis is made if two or more criteria are endorsed.  Since this is our target rule and the 
primary goal of our algorithm is to identify a diagnostic short-form as similar as possible in 
outcome to the current rule, we utilize the same technique of summing items within a subset.  To 
ensure we can sum across items, we included Step 1 where we assess the dimensionality of the 
item set.  Unidimensionality is not a fundamental assumption necessary for our algorithm but 
rather a check to ensure the items being assessed underlie a single dimension to allow us to sum 
across the respective items.  If multiple dimensions are found using factor analysis and/or 
evidence were found in other literature, then the algorithm would need to be re-run for every 
additional dimension found. 
 Constructing short-forms have been criticized on various grounds, the most common 
criticism dealing with inequivalence to the full-length form.  More specifically, if the full-length 
form was designed to be representative of a certain content domain, removing any of the items 
has the potential to narrow the content, leading to an inadequate representation of the breadth of 
the construct [Smith et al., 2000].  In our study, we found that diagnostic short-forms excluding 
“Neglected major roles to use” (C5) and/or “Activities given up to use” (C7) perform as well as 
the current rule in terms of correlation, diagnostic accuracy and prevalence.  In addition, there 
are four conceptual domains that each of the 11 AUD criteria fall into (Table 1.1) which 
represent the full content domain for AUD [Horvath et al., 2016] and excluding these two 




However, further validation using external validators of AUD needs to be undertaken to ensure 
the diagnostic short-forms are representative of the full AUD content domain. 
Additional criticism deals with the failure to show that short-forms have adequate 
overlapping variance with the full-length form using independent administrations.  In our study, 
we use the correlation between each subscale and the full set of items based on a single 
administration, which can lead to spuriously inflated correlations.  The best way to solve this 
problem would be to administer both the full and short versions separately to the same 
participants, but given our reliance on the NESARC data set, we lack this data.  Instead, at 
correlation Step 3, in an attempt to mitigate this concern, we estimated 95% confidence intervals 
and took a conservative approach as to which correlations move to the next step.  However, in 
future work we could consider applying Levy’s (1967) correction to account for the overlap of 
measurement errors using common data [Bohlmeijer et al., 2011]. 
Although we were able to replicate our findings in a separate general population sample, 
we would recommend that before any changes are suggested to the DSM-5, these results be 
replicated on clinical samples.  It is also important to point out that each step in our 
methodological process uses some type of comparison to the current DSM-5 rule, as if it is the 
best diagnostic target for AUD.  Hence, in terms of recommendations, we cannot say that we are 
deriving a more valid criteria-based definition of AUD than the DSM-5, because implicitly the 
method is assuming the current DSM-5 rule for AUD is already the most valid we have (and 
many would argue that it is at this current time).  The current method identifies shorter criteria 





 The primary difference between our proposed methodology and other traditional “static” 
test-shorting methods is that we are providing a shorter alternative that acts as similarly as the 
full set.  In addition, other traditional methods for criteria selection – including regression 
techniques like LASSO, leave-one-out cross-validation (LOOCV) [Black et al., 2017] and least 
absolute shrinkage [Finkelman et al., 2017] or factor analysis techniques like EFA and CFA 
[Singh et al., 2009; Bohlmeijer et al., 2011] – all choose items to establish a finite list of 
potential short-forms. In contrast, we start with an exhaustive list of all possible subscales and 
choose a whole set of subscales within each 𝑝, which allows for the next steps in our 
methodology (prevalence, diagnostic accuracy, DTF) to assess more diagnostic short-forms.  
Utilizing an exhaustive list allows for further investigation into some of the worst subscales and 
subsequent diagnostic short-forms, which can also provide useful information in test-shortening.  
Further, if the data being used only have information on a finite set of items, our methodology 
can determine the optimal diagnostic short-form among those possible items.  Lastly, many 
traditional methods utilize sensitivity and specificity to determine an optimal threshold for 
diagnosis [Black et al., 2017; Finkelman et al., 2017].  However, our methodology has an 
additional requirement that calibrates for prevalence to ensure that the final diagnostic short-
forms chosen have similar prevalence estimates when compared to the current rule.  
Each of the optimization steps are not new when compared to other traditional test-
shortening methods, but the order in which we implement them in our algorithm, the 
combination of all steps as a macro, and the flexibility we allow provides a novel approach to 
investigating possible short-form alternatives that perform as similarly as possible as using the 
full set.  With a changing environment for DSM revisions, traditional test-shortening methods 




that identifies diagnostic short-form alternatives that perform as well as the current rule in a 




1.6 TABLES AND FIGURES 



















Substance is often taken in larger amounts or over a 







There is a persistent desire or unsuccessful efforts to 





A great deal of time is spent in activities necessary to 
obtain substance, use substance, or recover from its 
effects 





major roles to 
use1 
2% 
Recurrent substance use resulting in a failure to fulfill 






Continued substance use despite having persistent or 
recurrent social or interpersonal problems caused or 
exacerbated by the effects of the substance 
C7 
Activities given 
up to use2 
2% 
Important social, occupational, or recreational activities 
are given up or reduced because of substance use 
Risky Use 
C8 Hazardous use1 12% 







Substance use is continued despite knowledge of 
having a persistent or recurrent physical or 
psychological problem that is likely to have been 
caused or exacerbated by substance 
Pharma-
cological 
C10 Tolerance2 10% 
Tolerance, as defined by either of the following: 
(a) A need for markedly increased amount of substance 
to achieve desired effect 
(b) A markedly diminished effect with continued use of 
the same amount 
C11 Withdrawal2 11% 
Withdrawal, as manifested by either of the following: 
(a) The characteristic withdrawal syndrome for alcohol 
(b) Substance (or a closely related substance) is taken 




N/A Recurrent substance-related legal problems 
+ The order of AUD diagnostic criteria presented follows the order listed in the DSM-5 manual [NIAAA, 2015] and 
the conceptual domains provide useful groupings [Horvath et al., 2016; Godier and Park, 2015] 
1 DSM-IV Abuse diagnosed with one or more abuse criteria within a 12-month period and no dependence diagnosis 
2 DSM-IV Dependence diagnosed with three or more dependence criteria within a 12-month period 
a Craving was not present in DSM-IV and was added to the DSM-5 criteria 





















Step 3  
Correlation of Subscales 
from Step 3 with Full 






– Step 4 
1 11 3 (27.3%) 0.718 (0.712 – 0.726) 3 
2 55 4 (7.3%) 0.836 (0.832 – 0.845) 8 
3 165 11 (6.7%) 0.889 (0.886 – 0.895) 33 
4 330 23 (7.0%) 0.921 (0.918 – 0.925) 92 
5 462 25 (5.4%) 0.944 (0.943 – 0.947) 125 
6 462 10 (2.2%) 0.963 (0.962 – 0.965) 60 
7 330 5 (1.5%) 0.977 (0.976 – 0.978) 35 
8 165 2 (1.2%) 0.987 (0.987 – 0.988) 16 
9 55 1 (1.8%) 0.995 (0.995 – 0.995) 9 
10 11 2 (18.2%) 0.998 (0.998 – 0.998) 20 
11a -- --  -- 
TOTAL 2046 86 (4.2%)  401 




















Figure 1.5 Difference in Prevalence between DSM-5 AUD and Diagnostic Short-Forms* (values 
greater than zero indicate DSF prevalence is higher than DSM-5 AUD prevalence, values less 
than zero indicate DSF prevalence is lower than DSM-5 AUD) – Step 5 
 
* Only 72 diagnostic short-forms that fall within 5% of DSM-5 AUD prevalence (out of the 401 




Figure 1.6 Sensitivity vs. 1-Specificity for 72 Diagnostic Short-Forms – Step 6 
 












Old vs. Young  Male vs. Female Non-White vs. White 
Any Mood and/or Anxiety 
Disorder vs. None 
Est. (SE) p-value Est. (SE) p-value Est. (SE) p-value Est. (SE) p-value 
510 4 1 -0.090 (0.079) 0.257 -0.251 (0.076) 0.001 0.096 (0.082) 0.245 0.007 (0.082) 0.930 
860 4 1 -0.014 (0.061) 0.822 -0.099 (0.056) 0.077 -0.211 (0.059) <0.001 -0.290 (0.066) <0.001 
864 4 1 -0.157 (0.068) 0.021  -0.023 (0.066) 0.729 -0.039 (0.066) 0.552 -0.327 (0.079) <0.001 
866 4 1 -0.213 (0.067) 0.001 -0.170 (0.068) 0.012 -0.235 (0.068) <0.001 -0.375 (0.080) <0.001 
884 4 1 0.031 (0.078) 0.687 -0.027 (0.066) 0.681 -0.224 (0.071) 0.002 -0.168 (0.074) 0.024 
892 4 1 -0.092 (0.069) 0.184 -0.140 (0.067) 0.038 0.051 (0.067) 0.448 -0.205 (0.077) 0.008 
894 4 1 -0.179 (0.067) 0.007 -0.305 (0.068) <0.001 -0.183 (0.068) 0.007 -0.312 (0.080) <0.001 
896 4 1 -0.274 (0.077) <0.001 -0.122 (0.082) 0.139 -0.088 (0.075) 0.243 -0.335 (0.092) <0.001 
988 4 1 -0.023 (0.061) 0.703 0.018 (0.056) 0.753 0.068 (0.060) 0.255 -0.078 (0.061) 0.198 
992 4 1 -0.309 (0.066) <0.001 -0.011 (0.066) 0.863 -0.028 (0.065) 0.662 -0.141 (0.072) 0.052 
1020 4 1 -0.256 (0.067) <0.001 -0.156 (0.069) 0.024 0.031 (0.067) 0.642 -0.114 (0.072) 0.117 
1154 4 1 -0.056 (0.063) 0.371 -0.045 (0.061) 0.462 0.136 (0.064) 0.034 -0.329 (0.069) <0.001 
1406 4 1 -0.081 (0.066) 0.222 -0.101 (0.062) 0.107 0.071 (0.066) 0.280 -0.392 (0.073) <0.001 
1526 4 1 0.025 (0.074) 0.730 -0.033 (0.065) 0.618 0.031 (0.069) 0.651 -0.063 (0.070) 0.371 
861 5 1 -0.065 (0.082) 0.425 -0.081 (0.079) 0.306 -0.028 (0.079) 0.728 -0.313 (0.097) 0.001 
863 5 1 -0.199 (0.077) 0.010 -0.299 (0.078) <0.001 -0.259 (0.078) 0.001 -0.348 (0.095) <0.001 
989 5 1 -0.272 (0.079) 0.001 -0.105 (0.078) 0.179 -0.007 (0.077) 0.929 -0.058 (0.085) 0.495 
378 6 2 -0.157 (0.073) 0.032 -0.026 (0.070) 0.716 0.092 (0.076) 0.225 -0.406 (0.083) <0.001 
345 7 2 -0.069 (0.068) 0.315 -0.095 (0.061) 0.120 -0.232 (0.065) <0.001 -0.163 (0.070) 0.019 
375 7 2 -0.029 (0.093) 0.755 -0.007 (0.089) 0.937 -0.008 (0.088) 0.928 -0.150 (0.096) 0.120 
120 8 2 -0.117 (0.106) 0.272 -0.073 (0.107) 0.495 0.057 (0.106) 0.588 -0.089 (0.110) 0.417 
a DSF label is the identifier given by the algorithm when all original subscales are enumerated and does not encode any specific information 
b Four rules were bypassed from assessment due to very high sensitivity (≥ 97%) and specificity (100%) estimates 
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Figure 1.7 Criteria Included/Excluded in the 8 Optimal Diagnostic Short-forms for DSM-5 
AUD* - Step 8 
 
* Ranked by highest to lowest Youden’s Index  
The number after each DSF is a label identifier given by the algorithm when all original subscales are 




    






Prevalence1 Sensitivity Specificity 
74 10 2 0.998 (0.998, 0.998) 0.191 (0.185, 0.196) 0.998 (0.997, 0.999) 1.000 (1.000, 1.000) 
26 10 2 0.998 (0.998, 0.998) 0.191 (0.185, 0.196) 0.998 (0.997, 1.000) 1.000 (1.000, 1.000) 
89 9 2 0.995 (0.994, 0.995) 0.190 (0.185, 0.196) 0.996 (0.995, 0.998) 1.000 (1.000, 1.000) 
344 8 2 0.988 (0.987, 0.988) 0.188 (0.183, 0.194) 0.986 (0.982, 0.990) 1.000 (1.000, 1.000) 
120 8 2 0.987 (0.987, 0.988) 0.184 (0.178, 0.190) 0.964 (0.957, 0.970) 1.000 (1.000, 1.000) 
375 7 2 0.978 (0.977, 0.979) 0.182 (0.176, 0.188) 0.953 (0.946, 0.960) 1.000 (1.000, 1.000) 
988 4 1 0.922 (0.919, 0.925) 0.213 (0.207, 0.218) 0.898 (0.887, 0.908) 0.949 (0.945, 0.953) 
1526 4 1 0.919 (0.916, 0.922) 0.246 (0.239, 0.253) 0.921 (0.913, 0.929) 0.913 (0.908, 0.918) 
1DSM-5 AUD prevalence in sample is 0.191 (95% CI: 0.185, 0.197) 
The number after each DSF is a label identifier given by the algorithm when all original subscales are 
enumerated and does not encode any specific information. P=# of criteria, M=threshold 
 
 




Figure 1.8. Descriptive Statistics (estimates with 95% CIs) on Optimal Diagnostic Short-Forms for DSM-5 AUD – Step 8 
 
The number after each DSF is a label identifier given by the algorithm when all original subscales are enumerated and does not encode any 
specific information. P=# of criteria, M=threshold 
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Table 1.6 Distribution of DSM-5 AUD Criteria and Selected Covariates in NESARC-III Split 
half 1, NESARC-III Split half 2 and Wave 2 NESARC 
Criterion / Covariate 
Split half 1 
(n=12,889) 





C1: Used larger amounts / longer 15.1% 14.3% 14.6% 
C2: Repeated attempts to quit/control 13.2% 12.7% 12.4% 
C3: Much time spent using 4.8% 5.1% 3.0% 
C4: Craving 10.9% 10.5% 4.1% 
C5: Neglected major roles to use 1.7% 2.0% 1.1% 
C6: Social/interpersonal problems 6.3% 6.3% 2.5% 
C7: Activities given up to use 1.7% 1.8% 1.0% 
C8: Hazardous use 11.6% 11.4% 11.1% 
C9: Physical/psychological problems 7.0% 7.3% 5.3% 
C10: Tolerance 9.6% 9.5% 8.2% 
C11: Withdrawal 10.5% 10.7% 7.9% 
    
Young (<= 44 years old) 52.4% 51.6% 52.2% 
Male 51.1% 50.3% 52.1% 
White 81.0% 80.6% 75.0% 
Any mood and/or anxiety disorders 22.8% 21.8% 17.9% 
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Figure 1.9 Criteria Included/Excluded in Optimal DSFs in both Split Halves* 
 
* DSFs ordered by p and combined Sensitivity, Specificity within split-half groups (Both, SH1, SH2) 
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Table 1.7 Fit Statistics with 95% CIs on Optimal Diagnostic Short-Forms for DSM-5 AUD 






Prevalence1 Sensitivity Specificity 
74 10 2 0.998 (0.998, 0.998) 0.162 (0.156, 0.168) 0.999 (0.998, 1.000) 1.000 (1.000, 1.000) 
26 10 2 0.998 (0.998, 0.999) 0.162 (0.156, 0.168) 0.998 (0.997, 1.000) 1.000 (1.000, 1.000) 
89 9 2 0.995 (0.995, 0.996) 0.162 (0.156, 0.168) 0.997 (0.996, 0.999) 1.000 (1.000, 1.000) 
120 8 2 0.988 (0.987, 0.989) 0.160 (0.154, 0.166) 0.987 (0.983, 0.992) 1.000 (1.000, 1.000) 
344 8 2 0.988 (0.987, 0.989) 0.159 (0.153, 0.165) 0.980 (0.974, 0.987) 1.000 (1.000, 1.000) 
247 7 2 0.977 (0.975, 0.978) 0.155 (0.149, 0.161) 0.956 (0.948, 0.965) 1.000 (1.000, 1.000) 
471 7 2 0.977 (0.976, 0.979) 0.154 (0.148, 0.160) 0.950 (0.942, 0.959) 1.000 (1.000, 1.000) 
502 6 2 0.964 (0.962, 0.966) 0.152 (0.146, 0.158) 0.938 (0.929, 0.948) 1.000 (1.000, 1.000) 
378 6 2 0.960 (0.958, 0.963) 0.151 (0.145, 0.157) 0.930 (0.918, 0.942) 1.000 (1.000, 1.000) 
474 6 2 0.960 (0.958, 0.962) 0.147 (0.141, 0.153) 0.907 (0.896, 0.919) 1.000 (1.000, 1.000) 
505 5 2 0.940 (0.936, 0.943) 0.145 (0.139, 0.151) 0.893 (0.880, 0.906) 1.000 (1.000, 1.000) 
476 4 1 0.908 (0.903, 0.913) 0.218 (0.212, 0.225) 0.927 (0.918, 0.937) 0.919 (0.914, 0.923) 
252 4 1 0.909 (0.903, 0.914) 0.218 (0.211, 0.225) 0.925 (0.915, 0.934) 0.919 (0.914, 0.923) 
507 3 1 0.878 (0.871, 0.884) 0.216 (0.209, 0.223) 0.916 (0.906, 0.927) 0.919 (0.915, 0.924) 
451 3 1 0.864 (0.857, 0.872) 0.210 (0.204, 0.217) 0.900 (0.888, 0.911) 0.923 (0.919, 0.927) 
3 3 1 0.864 (0.856, 0.871) 0.210 (0.203, 0.217) 0.896 (0.885, 0.906) 0.923 (0.919, 0.927) 
1DSM-5 AUD prevalence in sample is 0.162 (95% CI: 0.156, 0.168) 
The number after each DSF is a label identifier given by the algorithm when all original subscales are 
enumerated and does not encode any specific information. P=# of criteria, M=threshold 
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Figure 1.10 Criteria Included/Excluded in Optimal Diagnostic Short-forms for DSM-5 AUD in 




    
Chapter 2 
Identification and Validation of Dimensional Short-Forms 
2.1 INTRODUCTION 
2.1.1 Binary vs. dimensional categorization and lengthy criteria sets 
The diagnostic criteria provided by the DSM-5 help clinicians diagnose subjects into distinct, 
non-overlapping categories [Potuzak et al., 2012; APA, 2013].  Not all listed criteria for a 
specific disorder (𝑃) must be observed to consider a diagnosis present, but rather a specified 
subset of criteria must be observed.  Once this minimum threshold is met, a disorder is 
considered to be present.  Whereas, if the subset of criteria observed falls below the threshold 
then the disorder is considered to be absent [Krueger and Bezdjian, 2009].  As discussed in the 
previous chapter, drinking that becomes problematic is given a diagnosis of AUD when a subject 
meets two or more of the 11 possible criteria associated with AUD during the same 12-month 
period. 
 In addition to binary classification (diagnosis vs. no diagnosis), there has been recent 
movement to incorporate a dimensional component to classification for many of the current 
disorders in the DSM [Kozak and Cuthbert, 2016; Kose and Cetin, 2017].  This dimensional 
component can be defined as a scale with three or more ordinal categories and uses the count of 
the specified diagnostic criteria [Kraemer, 2007].  As the number of criteria present increases, 
the severity diagnosis of the disorder increases.  The DSM-5 has started to incorporate a 
dimensional approach to classification for many of the current disorders.  For example, the 
current severity rule for DSM-5 AUD using the original 11 criteria has four categories:  None (0-
1 criteria), Mild (2-3 criteria), Moderate (4-5 criteria) and Severe (6-11 criteria) [APA, 2013]. 
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A diagnostic system based on easily observable signs and reportable symptoms that 
results in a diagnosis or no diagnosis has considerable utility for communication, prognosis, and 
treatment [Hasin et al., 2013].  This approach allows for extensive testing of diagnostic 
agreement which has resulted in high reliability estimates for diagnoses among DSM iterations 
over the years.  However, there are significant disadvantages of binary categorizations, which 
include the grouping of subjects of varying severity into a single category.  More specifically, 
there is meaningful variation even among those subjects who fall clearly above (or below) the 
threshold.  Unfortunately, this information may be lost when subjects are grouped into a single 
diagnosis while utilizing a binary classification approach.  This consequence makes validating 
diagnoses even more difficult [Hasin et al., 2013; Helzer et al., 2006].   
Since there is no gold standard diagnosis in psychiatry, validation of a diagnostic measure 
will need to utilize associations with external validators of disorder (e.g. family history, impaired 
functioning, treatment seeking).  Use of a dimensional measurement of disorder rather than a 
dichotomous diagnosis is better suited for assessing validity as dimensions increase the ability to 
identify clinically important differences among those subjects who fall above or below the 
threshold [Goldberg, 2000; Helzer et al., 2006].  Validation of diagnoses through external 
validators can be explored more thoroughly to identify these clinically important individual 
differences when subjects are categorized on a severity spectrum, rather than simply being 
diagnosed as having the disorder or not having the disorder. 
Binary diagnoses and dimensional severity measures within the DSM use the same set of 
criteria for each disorder to categorize subjects. It has been previously noted that some criteria 
sets are lengthy, which may make them inefficient and problematic for some clinical or research 
purposes.  As previously described in Chapter 1, these problems can include issues with clinical 
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utility [Krupinski and Tiller, 2001; Learman et al., 2003; Zimmerman et al., 2006; Lacson et al., 
2010; Miettunen and Jaaskelainen, 2010; Gross et al., 2012], increased heterogeneity of disease 
presentation [Galatzer-Levy and Bryant, 2013] and a potential for redundancy among items 
[Tank et al., 2005].  With the adoption of a continuous improvement model for DSM revisions 
by the APA, there is an increased motivation to determine areas of improvement [Hales et al., 
2014; First, 2016; Moran, 2017].   
The APA anticipates five types of proposed changes that could be made to DSM-5 and 
our method is focused on Type 1 proposals dealing with changes to an existing diagnostic 
criteria set.  For Type 1 proposals, the APA requires evidence that the proposed changes would 
markedly improve at least one of the following: Type 1a - improve validity of an existing 
diagnostic criteria set, Type 1b - improve reliability of a diagnostic criteria set, without an undue 
reduction in validity, Type 1c - improve clinical utility of a diagnostic criteria set, without a 
reduction in validity or reliability and Type 1d - reduce deleterious consequences associated with 
a diagnostic criteria set, without a reduction in validity [American Psychiatric Association 
(APA), 2018].  Focusing on improving the validity and clinical utility (Type 1a and Type 1c), we 
develop a methodology that identifies valid, shorter, more efficient and practical versions of 
existing criteria sets. 
2.1.2 Previously described methodology for identifying optimal diagnostic short-forms 
In Chapter 1, a methodology was developed that provided a way of identifying short-forms of 
criteria sets that were subsets of an original full-length criteria set (𝑝) along with a single 
specified threshold (𝑚) to indicate diagnosis.  The primary goal of our methodology was to 
identify diagnostic short-form alternatives using a data-driven tool that resulted in a diagnosis as 
similar as possible to the original, full-length version.  More specifically, using AUD, each step 
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in our methodological process used some type of comparison (i.e. maximizing correlation, 
sensitivity, specificity) with the current DSM-5 rule for AUD.  In this sense, our primary target 
was the current DSM-5 binary rule for AUD in identifying diagnostic short-forms.  Inherently, 
we were taking the current DSM-5 diagnosis to be the gold-standard, hence the method was not 
deriving a more valid criteria-based definition of AUD, but one that acted as similarly as possible 
to the existing one.  In deriving our next methodology in the present Chapter, we will not assume 
validity of the current DSM-5 rule but will explore external validity of diagnostic rules utilizing 
external validators of disorder.  In addition, rather than identify binary diagnostic short-form 
alternatives with a single threshold, we will identify alternative severity rules (i.e. dimensional 
short-forms) with multiple thresholds using external validators of disorder as our primary target. 
2.1.3 Validity 
Unlike most medical diagnoses, e.g. a cancer tumor, or a broken leg which can be biopsied or 
seen by X-ray, psychiatric disorders have yet to be observed directly through any physical or 
biological technology; although there is a strong pursuit of brain imaging biomarkers for this 
purpose [Gelernter and Kranzler, 2009, 2010; Hartz and Bierut, 2010; Goldstein and Volkow, 
2011].  Instead, psychiatric disorders are diagnosed based on psychological and behavioral 
experiences reported by or observed by others in the person.  From a measurement perspective, 
psychiatric disorders cannot be directly observed but instead can be considered latent constructs 
that manifest themselves as phenomena we can observe.  A latent construct provides a verbal 
surrogate to describe unobservable phenomena (i.e., disorders) recognizing that these phenomena 
may never be known directly or with complete accuracy [Edwards and Bagozzi, 2000].  The 
primary purpose of the DSM is to provide a standard set of observable signs and symptoms that 
can be used to infer the diagnosis of the underlying latent construct, the psychiatric disorder.  
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The DSM provides an evolving checklist of diagnostic criteria that are quantifiable and directly 
observable measures corresponding to each disorder, which are used to diagnose subjects has 
having the disorder when a subset of possible criteria is met.   
While the DSM provides a standard diagnostic guide, there are still questions as to 
whether the DSM effectively addresses issues of validity which lead the National Institute of 
Mental Health (NIMH) to propose an alternative nosology; the Research Domain Criteria 
(RDoC) [Whooley, 2014].   In contrast to the DSM, RDoC encourages researchers not to think in 
terms of discrete categories but rather identify common underlying biological, neurological, or 
genetic causes with the intention to achieve a valid system for categorizing mental disorders 
rooted in neurology [Whooley, 2014].  Although, RDoC still remains in preliminary, abstract 
stages which means the DSM is still the primary diagnostic classification system for diagnosing 
mental health disorders and why our methodologies focus on improving DSM validity.   
We propose an alternative method for static test shortening and apply it to develop the 
best diagnostic short-forms for Alcohol Use Disorder (AUD) based on data collected on subjects 
who were evaluated on the full set of 11 DSM-5 AUD criteria.  Since the creation of the DSM in 
1952, there has been roughly one revision per decade, with each iteration attempting to reach the 
“truth”.  The strength of each new iteration of the DSM has been well-founded in reliability.  As 
applied to the DSM, reliability refers to how reproducible the diagnosis is and assesses the 
proportion of variability in the diagnosis that is due to measurement error [Furr, 2011].  On the 
other hand, a weakness and main topic of DSM critics involves validity, or lack thereof [Woo 
and Rey, 2005; Vieta and Phillips, 2007; Blom and Oberink, 2012; Bassam et al., 2014]. 
In general, the validity of a measure of some phenomena is an assessment of how well it 
actually captures the true phenomena it is meant to measure.  For the DSM, validity assesses if 
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and how well the criteria and diagnosis measure the psychiatric disorder they purport to measure 
[Nelson-Gray, 1991].  Validity introduces the idea of operationalizations – any time one 
translates a construct into a functioning and operating reality (the operationalization) [Trochim, 
2006].  Traditionally, psychometric theory organizes validity into three major types: (1) construct 
validity – the degree to which inferences can legitimately be made from operationalizations in 
the study to the theoretical constructs on which those operationalizations were based, (2) 
criterion-related validity – the performance of the operationalization against some gold standard 
criterion, and (3) content validity – the comparison of the operationalization against the relevant 
content domain for the construct [Nunnally and Bernstein, 1994; Trochim, 2006].   
More contemporary views hold that construct validity is the unifying form of validity, 
subsuming both content and criterion validity and deals with translating any construct into an 
operationalization [Trochim, 2006; Strauss and Smith, 2009].  According to Trochim (2006), in 
order to establish construct validity, the researcher starts with a theory of how measures are 
related to each other and other theoretical terms (a theoretical pattern), the researcher then 
provides evidence through observation that the measures actually behave that way in reality 
(observed pattern).  Following contemporary views of construct validity, in order to build 
evidence for valid diagnoses, one needs to find evidence that the observable measures of a 
construct behave as expected.  This aspect of validity is known as convergent validity, such that 
behaving as expected is operationalized by demonstrating the observable measures correlate with 
(converge with) theoretically related constructs. 
Robins and Guze (1970) were one of the first to translate establishing validity of 
psychiatric disorders from a concept to an actual empirical method to be tested.  To create an 
observable measure representing a theoretical construct, they proposed the following formal 
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components to be identified: clinical description; laboratory studies; delimitation from other 
disorders; follow-up studies; and family studies.  Using these components, Robins and Guze 
(1970) provided evidence that subsequently underpinned the distinction between schizophrenia 
and schizophreniform disorder in the transition from DSM-II to DSM-III [Kendell and 
Jablensky, 2003].  Later, Kendler (1980) elaborated on these components to incorporate a 
temporal differentiation including antecedent (e.g., familial aggregation, precipitating factors), 
concurrent (e.g., psychological tests) and predictive validators (e.g., treatment seeking).  Using 
these expanded components, Kendler (1980) demonstrated that paranoia (simple delusional 
disorder) was potentially a distinct syndrome rather than a mild form of schizophrenia [Kendell 
and Jablensky, 2003]. 
To assess convergent validity of a measure of a latent construct, it is necessary to identify 
other observable factors theoretically expected to be related to the construct of interest, and then 
show that they are actually related as expected.  Following the schema devised by Robins and 
Guze (1970) and expanded upon by Kendler (1980), we can identify several external validators 
to assess the best dimensional set of criteria for SUD.  These validators are broken out 
temporally where antecedent validators are variables that have a role in the etiology of the 
disorder (e.g., family history, early onset, precipitating factors), concurrent validators are 
biological and psychological variables assessed during the disorder (e.g., treatment seeking), and 
predictive validators are related to course of illness (e.g., low occupational attainment) [Hasin et 
al., 1997; Hasin and Paykin, 1999a; Hasin and Paykin, 1999b; Nelson-Gray, 1991].   
Given a set of external validators, one could proceed to assess convergent validity using 
each one separately.  In the present study we develop a method in which we use a composite 
validator that combines information from all of the different validators to facilitate our ability to 
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systematically identify an optimally valid dimensional criteria set for SUD.  Following a domain 
sampling point of view, the selected validators are considered to be sampled from a much larger 
domain of possible validators (antecedent, concurrent, predictive) of the construct [MacCoun, 
2013].  Hence the external validators are themselves modeled as measures of a single coherent 
latent validator construct.  With diagnostic criteria providing a quantifiable measure of the 
specified latent disorder, and the external validators providing a quantifiable measure of the 
composite theoretically related validation construct, we can assess convergent validity (see 
Figure 2.1).  More specifically, we can identify subsets of criteria that associate (i.e., correlate) 
most strongly with the composite validator. 
2.1.4 A new method for identifying valid dimensional short-forms 
In the present study, we propose a data-driven multi-step process that identifies optimally valid 
dimensional short-forms in a systematic way.  Following our previous methodology, our 
motivating example is to empirically identify the optimal dimensional short-forms for AUD from 
the current DSM-5 criteria set.  However, in the present method focused on validity, we are no 
longer using the current DSM-5 severity rule as our primary target.  Instead, we will create a 
composite of external validators that are theoretically related to the disorder and use that 
composite measure as our primary target.  Then, following the notion of convergent validity, we 
will identify dimensional short-forms that are most related to the external composite validator 
(ECV) in ways that would be theoretically justified.  Specifically, the goals of the procedure are 
to obtain nested subsets of the original criteria set that (1) maximize the association between the 
ECV and the newly constructed subscales from subsets of criteria and (2) obtain associated 
severity cut-offs (i.e. dimensional short-forms) that maximally discriminate on ECV based on R-
Squared (𝑅2) across the respective severity spectrum (e.g. None, Mild, Moderate, Severe).  At 
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the end of this empirically driven multi-step process, a list of optimal dimensional short-forms 
for AUD will be recommended. 
2.2 METHODS 
2.2.1 Data source 
To remain consistent with our motivating example from Chapter 1, we will continue to use AUD 
to explore our second methodology.  As previously described, the DSM-5 provides a 
pathological set of behaviors that form the 11 diagnostic criteria used to diagnose AUD.  These 
behaviors fall into four broad categories of Impaired Control, Social Impairment, Risky Use and 
Pharmacological Indicators (see Table 1.2) [Horvath et al., 2016].  With the DSM-5, there is a 
dimensional aspect to all SUDs where the diagnosis is ordered by severity as None (0-1 criteria), 
Mild (2-3 criteria), Moderate (4-5 criteria) and Severe (6-11 criteria).  The goal of the present 
study is to develop a method to systematically identify valid dimensional short-form alternatives 
to DSM-5 AUD severity.  Specifically, we will find optimally valid cut-offs that create four 
severity categories using criteria counts of subsets from the full-length set. 
As in Chapter 1, the data we will use to empirically identify dimensional short-forms for 
AUD comes from the National Epidemiologic Survey on Alcohol and Related Conditions-III 
(NESARC-III) conducted by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 
from 2012-2013.  The NESARC-III survey was conducted on a nationally representative sample 
of 36,309 non-institutionalized U.S. civilians 18 years or older and sampling weights are applied 
to account for non-response and oversampling that occurred among Hispanics, African 
Americans and Asians [Grant et al., 2014, 2015a].  Criteria for AUD were measured using the 
Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS-5) which has 
been shown to have high reliability and validity [Grant et al., 2015b; Hasin et al., 2015].  The 
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analytic sample used are those NESARC-III participants who reported having at least one drink 
of any kind of alcohol within the past year (𝑛 = 25,778).  Among current drinkers, 81% were 
diagnosed as having No Disorder, 10% Mild AUD, 4.4% Moderate AUD and 4.7% Severe 
AUD. 
2.2.2 External validators of AUD 
The 11 diagnostic criteria discussed in Chapter 1 represent observable and quantifiable measures 
of AUD.  The primary goal of our methodology is to find dimensional short-forms from these 11 
criteria that are most valid in terms of how they associate with external validators that are 
theoretically related to AUD.  The external validators chosen need to be well-established 
correlates of AUD to conduct convergent validation.  After assessing the literature, Table 2.1 
provides the external validators chosen from each temporal category.   
For antecedent validators, we use family history of alcoholism because AUDs have a 
strong heritable component resulting in family history being used consistently as a validator in 
psychiatry [Robins and Guze, 1970; Feighner et al., 1972; Kendler et al., 2000; Gelernter and 
Kranzler, 2009, 2010; Kendler, 2012].  Those diagnosed with AUD should be more correlated 
with family history of AUD than those who are not diagnosed and severe cases of AUD should 
be more correlated with family history than mild cases of AUD [Milne et al., 2009].  Three more 
antecedent validators include early initiation of drinking (younger than 18 years old) which has 
been proven to increase the risk for AUD [Grant and Dawson, 1998; Ridenour et al., 2005; 
Dawson et al., 2008] along with risky drinking habits [Hasin et al., 2017] and history of violence 
[Braun et al., 2000; Lee et al., 2009; Hicks et al., 2010; Latvala et al., 2011; Grant et al., 2012). 
For concurrent validators, we chose whether a subject has gone into any type of alcohol 
rehabilitation program.  This is an important type of treatment, which has been shown to be 
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applicable to alcohol and drug disorders in NESARC [Grant et al., 2007; Hatzenbuehler et al., 
2008; Keyes et al., 2008].  Moreover, treatment seeking is associated with AUD severity with 
the percentage of those seeking treatment increasing from Mild to Moderate to Severe AUD 
(2.7% to 4.9% to 21.3%, respectively) [Grant et al., 2015a].  Also, those with SUDs have worse 
functioning than others [Hicks et al., 2010] and since SUD severity is related to dysfunction 
[Hasin et al., 2007; Compton et al., 2007], we chose to utilize mental and physical quality of life 
(QoL) measures for two additional concurrent validators.  These norm-based measures come 
from the Short-Form 12 v.2 (SF-12v2) which is reliable, valid and widely used for current 
functioning measures [Gandek et al., 1998].  The last concurrent validator is whether the subject 
had any issues with their neighbors, friends or relatives.  This validator deals with the topic of 
life events, and while they can be outside the control of the subject, a negative pattern of events 
can indicate poor psychosocial functioning [Skodal et al., 2011].   
Lastly, predictive validators involve consequences of disorder and while NESARC-III is 
not prospective, it still provides indicators of relevant outcomes.  We chose to use 
unemployment, poverty and legal problems as these are important life course indicators that are 
often impaired in those with substance use disorders [Braun et al., 2000; Lee et al., 2009; Hicks 
et al., 2010; Latvala et al., 2011; Grant et al., 2012]. 
2.2.3 Overview of steps for identifying optimal dimensional short-forms 
We propose the following empirically driven process to identify optimally valid dimensional 
short-forms.  Each step specified below is elaborated on further in the next section within the 
context of AUD. 
Step 1: Determine list of external validators and confirm fit of Structural Equation Model 
(SEM) relating latent disorder with latent composite validator (Figure 2.1) 
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Step 2: Extract factor scores from latent composite validator in Step 1 and standardize to 
create the External Composite Validator (ECV) 
Step 3: Form all possible subscales from subsets of the full-length criteria set 
Step 4: Identify an optimal ranking of criteria to be included in subscales from Step 3 
based on the subscale correlations with ECV 
Step 5: Form all possible dimensional short-forms with 𝐶 + 1 severity categories using 𝐶 
severity cut-offs across all possible locations within the optimal subscales from 
Step 4 
Step 6: Identify an optimally valid ordered set of dimensional short-forms from Step 5 
based on maximizing 𝑅2 in regressions predicting ECV 
The primary goal for our methodology is to identify dimensional short-forms from the original 
set of diagnostic criteria that associate most strongly with the external validators and hence are 
optimally valid.  The use of an external composite validator, which extracts the common 
variance among all external validators, facilitates the discovery of dimensional short-form 
alternatives that associate most strongly with all the validators simultaneously.  Another goal of 
the procedure is to provide a ranking of importance of the criteria that are included in the 
dimensional short-form for maximizing validity.  This ranking identifies an optimally valid 
group of nested subscales such that the criteria in the 𝑝 − 1𝑡ℎ subscale are nested in the 𝑝𝑡ℎ 
subscale.  Finally, the method identifies the best severity cut-offs maximizing convergent 
validity in such a way that across different length dimensional short-forms the cut-offs are 
naturally ordered, i.e. higher cut-offs required when more criteria are included.  Random 
variability is statistically taken into account using 95% confidence intervals derived with non-
parametric bootstrapping [Efron and Tibshirani, 1986].  All estimates of association incorporate 
the NESARC-III sampling weights.  Once the optimally valid ordered set of dimensional short-
forms is identified, we can assess whether the short-forms exhibit better validity than the current 
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DSM-5 severity rule.  Moreover, we can assess whether short-forms with less criteria have non-
inferior or even superior validity to those with more criteria.  
2.2.4 Sensitivity Analysis: Demonstrate performance using alternative forms of ECV 
The ECV was constructed as a single summary measure representing the construct of “AUD 
risks/problems”.  Each external validator was selected based on its theoretical importance as an 
indicator of “AUD risks/problems”.  However, a simple question to ask is, “how valid is our set 
of validators”?  While we may not be able to provide a complete answer to that question, and we 
encourage researchers to use multiple validators from different antecedent, concurrent, predictive 
domains, we do provide some insight about the robustness of the results to the choice of 
validators within the set.  Indeed, if the reflective model assumption of the MIMIC model is 
correct, these indicators are considered to be interchangeable and can be thought to be sampled 
from a larger domain of possible indicators of “AUD risks/problems”.  Following this notion, we 
explore the robustness of our methodology using different versions of ECV based on which 
validators are included in the derivation. 
2.2.5 Demonstrate performance of dimensional short-forms identified in NESARC-III on a 
second data source (Wave 2 NESARC) 
As in Chapter 1, we tested the performance of the methodology on a completely new data source, 
Wave 2 NESARC.  We conducted our analysis on the subsample of Wave 2 NESARC 
participants, who reported they were current drinkers (𝑛 = 22,177).  Among current drinkers 
and using the current DSM-5 AUD Severity rule, 83.7% were diagnosed as having No Disorder 
(0-1 criteria), 10.5% Mild AUD (2-3 criteria), 3.4% Moderate AUD (4-5 criteria) and 2.4% 
Severe AUD (6-11 criteria).  Participants’ current drinker status and severity rule were defined in 
the same manner as in NESARC-III and the 11 criteria for DSM-5 AUD are conceptually the 
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same as well.  However, there were changes to four of the 11 DSM-5 AUD criteria in terms of 
the questions that go into creating the final criterion in NESARC-III compared to Wave 2 
NESARC which are detailed in Chapter 1. 
2.3 RESULTS 
2.3.1 Step 1: Determine list of external validators and confirm fit of Structural Equation 
Model (SEM) relating latent disorder with latent composite validator 
External validators were chosen based on literature reviews and content knowledge combined 
with availability of the measures in the dataset (Table 2.1).  A multiple indicator multiple cause 
(MIMIC) latent factor model was fit to all the external validators with antecedent validators as 
risks (or “causes”) of the latent composite validator and concurrent and predictive validators as 
consequences (or “indicators”) of the latent composite validator (right side of Figure 2.2).  We 
conceptualize the external composite validator as a construct of “AUD risks/problems”.  For 
consistency, each of the external validators were coded so that higher values of the validators 
indicate higher risks or problems.  Factor loadings from the MIMIC model (Table 2.2) indicate 
that all validators are significantly associated with the ECV indicating each is associated with 
more severe “AUD risks/problems”.  We note that very high WHO risk drinking level and 
history of violence have the strongest positive loading factors of 0.863 and 0.738, respectively. 
The MIMIC model has good fit by root mean square error of approximation (RMSEA) ≤ 0.06 
(RMSEA = 0.022) and comparative fit index (CFI) ≥ 0.90 (CFI = 0.901) [Hu and Bentler, 1999]. 
 Given a good fit for the measurement of the ECV via the MIMIC model, it was then 
important to check the association of the ECV with the AUD criteria.  To do this, we assessed 
the fit of the full SEM (Figure 2.2) which links the diagnostic criteria to the external validators 
through a correlation between their respective latent factors.  We found good model fit based on 
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RMSEA (0.026) and CFI (0.932).  Moreover, the relationship between ECV and AUD (see 
pathway between AUD and ECV in Figure 2.2 was found to have a regression coefficient of 
0.918.  Hence, we confirm that the information provided by the chosen external validators can be 
reduced to a single composite measure that captures all common variability in them which is 
related to the AUD criteria.  
2.3.2 Step 2: Extract factor scores from latent composite validator in Step 1 and standardize to 
create the External Composite Validator (ECV) 
Based on confirmation from Step 1 that the SEM relating the ECV and the AUD criteria fits 
well, factor score estimates were extracted from the MIMIC model for each individual in the 
NESARC-III data sample of current drinkers.  Figure 2.3 provides the distribution of ECV in the 
sample of current drinkers and Table 2.3 stratified by demographics (i.e., sex, age, race).  Even 
though there were subjects with missing values for the antecedent external validators, we were 
able to define ECV for 99% of current drinkers in our sample (𝑛 = 25,500).  However, since 
missing values for antecedent validators means the ECV will be missing, we recommend 
imputing missing values if the proportion missing exceeds 5% [Graham and Hofer, 2000].  In 
Figure 2.3, the ECV ranges from -1.634 to 4.900 with higher ECV values indicating more 
serious “AUD risks/problems”.  In Table 2.3, mean ECV decreases as age increases (all age 
groups are statistically different from the 18-24 year group) and mean ECV is statistically 
different across all races when compared to White, non-Hispanic (𝑝 < 0.001) but not 
statistically different between males and females (𝑝 = 0.6566). 
Figure 2.4 shows the correlation between the ECV and each of the external validators 
used to create it.  The mental QoL measure was the most correlated with ECV (𝑐𝑜𝑟𝑟 = 0.615) 
along with history of violence and legal problems as the next most correlated validators with 
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ECV (𝑐𝑜𝑟𝑟 = 0.561 and 𝑐𝑜𝑟𝑟 = 0.546, respectively).  The medium WHO risk level was the 
least correlated with ECV (𝑐𝑜𝑟𝑟 = 0.057).  
Lastly, Figure 2.5 shows the distribution of ECV by the sum count of all 11 AUD criteria.  
While there is substantial variability of the ECV within each count value, there is a clear 
increasing trend in the ECV by increasing count.  The current DSM-5 severity cut-offs are also 
indicated in Figure 2.5. We find a distinctly higher ECV distribution for those with 1 vs 0 criteria 
count, both of which are combined as “None” by DSM-5, and we see a wide variability in ECV 
across the Severe categories 6-11.  These observations indicate the grouping of severity cut-offs 
of the current DSM-5 might not be optimal for discriminating individuals on the ECV, hence the 
DSM-5 severity cut-offs may have sub-optimal validity.  A formal test of this will be made in the 
next steps of the method. 
2.3.3 Step 3: Form all possible subscales from subsets of DSM-5 AUD criteria 
As was previously described in Chapter 1, there are 11 diagnostic criteria associated with DSM-5 
AUD resulting in 2,047 possible subsets of criteria of varying size, where  𝑝 = 1, … , 11.  
However, since there will be three cut-offs (𝑐 = 3) incorporated to create the four severity 
categories (𝑐 + 1 = 4) in subsequent steps, we only create subsets of size 𝑝 = 3, 4, … , 11 
reducing the overall number of subsets possible to 1,981.  Table 2.4 provides a breakdown of the 
number of subsets by size  𝑝.  Once all possible subsets have been enumerated, we take the 





    
2.3.4 Step 4: Identify an optimal ranking of criteria to be included in subscales from Step 3 
based on the subscale correlations with ECV 
In this screening step, we narrow down the list of all 1,981 subscales by examining the 
correlation between each subscale and the ECV.  Figure 2.6 provides the Pearson correlations 
with ECV for all 1,981 subscales by the size of the subscale 𝑝, where 𝑝 = 3, 4, … , 11.  On 
average, the correlation coefficients increase as the number of criteria included in the subscale 
increase.  But, more importantly we see variability within each set of subscales of the same size 
𝑝, indicating some subscales have higher validity than others even with the same number of 
criteria included in the subscale.  Interestingly, some subscales with less criteria included 
outperform those with more criteria included.  For example, there are subscales with only three 
criteria included (“Craving” (C4), “Social/interpersonal problems” (C6), “Withdrawal” (C11)) 
that have a higher correlation with ECV than subscales with eight criteria included (“Used larger 
amounts/longer” (C1), “Repeated attempts to quit/control” (C2), “Much time spent using” (C3), 
“Neglected major roles to use” (C5), “Activities given up to use” (C7), “Hazardous use” (C8), 
“Physical/psychological problems” (C9), “Tolerance” (C10)).  This suggests some criteria are 
more important than others to the validity of the final severity scale.  Also, some subscales of 
size 𝑝 = 7, 8, 9, 10 have a higher correlation with the ECV than when using the full set of 11 
criteria suggesting some criteria may even be compromising the validity of the severity scale.   
 To identify the optimal ranking of criteria to be included, we found the subscales with the 
highest correlation with the ECV for each 𝑝 = 3, 4, … , 11 that also satisfied the nested criteria 
property, i.e. that the criteria included in the 𝑝 − 1𝑡ℎ subscale are nested in the 𝑝𝑡ℎ subscale.  For 
the present AUD example, Figure 2.7 provides the optimal group of nested subscales.  These 
nine subscales are the top ranked subscales based on correlation with ECV across 𝑝 and they also 
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satisfy the nested criteria property.  Specifically, the three criteria included in the 𝑝 = 3 subscale 
are included in all subscales where 𝑝 ≥ 3, the four criteria included in the 𝑝 = 4 subscale are 
included in all subscales where 𝑝 ≥ 4 and so on, up until 𝑝 = 11.   
We find the top four ranking criteria included for optimal validity of AUD severity 
include at least one criterion from each of the four conceptual domains.  That is, the 𝑝 = 4 
subscale has “Craving” (C4) from Impaired Control, “Social/interpersonal problems” (C6) from 
Social Impairment, “Physical/psychological problems” (C9) from Risky Use and “Withdrawal” 
(C11) from Pharmacological Indicators.  We note that the conceptual domains were not 
explicitly used in the derivation of the top criteria.  Criteria ranking of importance to validity was 
followed by “Tolerance” (C10), “Neglected major roles to use” (C5), “Much time spent using” 
(C3) and “Repeated attempts to quit/control” (C2).  On the other hand, “Used larger 
amounts/longer” (C1), “Hazardous” (C8) and “Activities given up to use” (C7) were the three 
least important to the validity since they were the first three to be dropped as they contributed the 
least to the correlation of the subscales with the ECV.  Interestingly, “Activities given up to use” 
(C7) was selected as the least important criterion for each data-driven method proposed. 
2.3.5 Step 5: Form all possible dimensional short-forms from the optimal group of nested 
subscales  
For DSM-5 AUD, the current severity rule has three cut-offs that create the following four 
severity categories: None (0-1 criteria), Mild (2-3 criteria), Moderate (4-5 criteria) and Severe 
(6-11 criteria).  With four severity categories, we need to determine all the possible ways to cut 
the sum count of criteria into four severity groups for the optimal group of nested subscales 
identified in the previous step.  The subscale with only three criteria included (𝑝 = 3) is the 
smallest 𝑝-size subscale we can assess because it can still maintain the four severity categories 
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(e.g. None (0 criteria), Mild (1 criteria), Moderate (2 criteria), Severe (3 criteria)).  With only 
three criteria, there are no variations as to where the three optimal cut-offs would be but as 𝑝 
increases, the number of ways to cut the subscales increases.   
Figure 2.8 provides an example of all the possible ways to cut subscales with four and 
five criteria included (𝑝 = 4, 5).  Again, there is only one way to cut a subscale with three 
criteria into four severity categories but when we increase the number of criteria in the subscale 
to four, there are then four different ways to cut the subscale into the four severity groups (see 
Options 1-4 in Figure 2.8).  Furthermore, when including a fifth criterion (𝑝 = 5), the number of 
ways to cut the subscale increases to 10 (see Options 1-10 in Figure 2.8).  Table 2.5 provides the 
number of ways to cut each subscale ranging in size from 𝑝 = 3 𝑡𝑜 11.  As the number of criteria 
included in the subscale increases, the total number of ways to cut the subscale into four severity 
groups increases providing a total of 495 possible ways to cut all nine nested subscales.  Of note, 
there are 165 ways to cut the full criteria set and the current severity rule for DSM-5 AUD is 
among them. 
2.3.6 Step 6: Identify an optimally valid ordered set of dimensional short-forms from Step 5 
based on maximizing 𝑹𝟐 in regressions predicting ECV 
We separately regressed the ECV on each of the 495 dimensional short-forms derived in Step 5 
treating the severity as four separate categories.  Figure 2.9 displays the 𝑅2 values by size of the 
dimensional short-form (𝑝) which range from 0.07 to 0.19 across all 𝑝.  Overall, the mean 𝑅2 
decreases as 𝑝 increases but this phenomenon is driven by poorly performing dimensional short-
forms which can be formed when more criteria are added.  For example, the worst performing 
dimensional short-form for 𝑝 = 11 has 𝑟2 = 0.07 with severity cut-offs that create the following 
severity categories: None (0-8 criteria), Mild (9 criteria), Moderate (10 criteria) and Severe (11 
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criteria).  These cut-offs are clearly not of interest and the 𝑅2 easily suggests them not to be 
considered.  
Figure 2.10 displays the 𝑅2 with 95% confidence intervals for the top performing 
dimensional short-forms as well as the current DSM-5 severity rule.  A schematic displaying the 
associated cut-offs for each of the these dimensional short-forms is shown in Figure 2.11.  Recall 
that the criteria included in all of the dimensional short-forms at this step within each 𝑝 are the 
same (see Figure 2.7).  The only thing being altered, is the location of the three cut-offs for 
defining four severity levels.  We find that all of the top dimensional short-forms require 0 
criteria for the No Disorder group as compared to the current DSM-5 severity rule which 
requires 0-1 criteria for No Disorder.  Moreover, the top four most valid cut-offs for the full set 
of  𝑝 = 11 also set the highest severity category to require more extreme values of 7, 8 or even 
9+ criteria in comparison to the DSM which collapses 6+ criteria into the highest category.  As a 
result, the DSM-5 severity rule has much lower validity (i.e. ability to predict the ECV) than 
rules with even fewer criteria but more optimal cut-offs. Also, using all 11 criteria does not 
produce the maximum estimates of 𝑅2.  Dimensional short-forms of size 𝑝 = 7, 8, 9, 10 have 
higher 𝑅2 than the 𝑝 = 11 rule (Figure 2.10).  For example, the top performing 𝑝 = 7 
dimensional short-form has 𝑟2 = 0.1905 with severity cut-offs that create the following severity 
categories: None (0 criteria), Mild (1-2 criteria), Moderate (3-5 criteria) and Severe (6-7 criteria).  
This dimensional short-form has a higher 𝑅2 than the top performing rule with all 11 criteria 
included (𝑟2 = 0.1884).   
To identify the final set of optimally valid dimensional short-forms across all 𝑝, we found 
those with highest 𝑅2 for each 𝑝 that also satisfied the ordered severity property, i.e. severity 
categorization cannot be more severe in a dimensional short-form with less criteria.  For 
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example, Figure 2.12 provides severity cut-offs for the top ranked dimensional short-forms based 
on 𝑅2 across 𝑝.  However, this set of dimensional short-forms fails the ordered property because 
the dimensional short-form of size 𝑝 = 9 has the following severity categories: None (0 criteria), 
Mild (1-2 criteria), Moderate (3-4 criteria) and Severe (5-9 criteria).  The 𝑝 = 8 dimensional 
short-form has the following severity categories: None (0 criteria), Mild (1-2 criteria), Moderate 
(3-5 criteria) and Severe (6-8 criteria).  This violates the ordered severity property condition 
because the 𝑝 = 8 dimensional short-form requires more criteria for a Severe categorization (6-8 
criteria) with one less criterion compared to 𝑝 = 9.  This property is also violated with 𝑝 = 7 as 
it requires 6-7 criteria for a Severe categorization and this has two less criteria than 𝑝 = 9. 
Since there is very little difference in terms of 𝑅2 across the top performing dimensional 
short-forms (Figure 2.10), we can identify another set that fits within the ordered set structure.  
However, there is optimality in making minimal changes so rather than change out both the 𝑝 =
7 and 𝑝 = 8 dimensional short-forms, we can make a single change with 𝑝 = 9.  Figure 2.13 
displays the optimal dimensional short-forms and the current DSM-5 AUD severity rule.  Using 
this set, we can determine whether these dimensional short-forms are significantly different from 
the DSM-5 AUD severity rule.  Figure 2.14 provides the test of the difference in  𝑅2 between 
each dimensional short-form and the current DSM-5 AUD severity rule.  All dimensional short-
forms except for 𝑝 = 3 are significantly better predictors of ECV than DSM-5 and hence are 
more valid measures of AUD severity.  Furthermore, we find in Figure 2.15 that all dimensional 
short-forms except for 𝑝 = 3 are not statistically inferior to the best 𝑝 = 11 severity rule. 
Another way to compare the optimal dimensional short forms to the DSM-5 severity is 
shown in Figure 2.16.  This figure provides mean ECV and 95% confidence intervals for each 
severity category comparing the current DSM-5 AUD severity rule with the best 𝑝 = 7 
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dimensional short-form among the final ordered set.  The None groups are not significantly 
different between the two rules but we see a significant difference in mean ECV for the Mild, 
Moderate and Severe groups.  The 𝑝 = 7 dimensional short-form requires six or more criteria to 
be present for a Severe categorization which is similar to using the full set of criteria (i.e., Severe 
(6-11 criteria)).  However, the mean ECV for the Severe group using 𝑝 = 7 is 2.13 (95% CI: 
2.02, 2.24) which is significantly larger than when using the DSM-5 severity where mean ECV is 
1.57 (95% CI: 1.49, 1.65).  Thus, the 𝑝 = 7 dimensional short-form is identifying subjects in the 
Severe group with a higher ECV score while still requiring at least six criteria to be present but 
having four less criteria in the dimensional short-form than the DSM-5. 
Finally, we can test whether the ECV acted as an adequate summary measure by 
assessing how these dimensional short-forms distinguished each individual external validator 
across the respective severity cut-offs.  Table 2.6 compares DSM-5 AUD Severity to the 𝑝 = 7 
dimensional short-form for each external validator.  The optimally valid 𝑝 = 7 dimensional 
short-form is able to maximally discriminate 10 of the 11 external validators better than the 
DSM-5 severity rule, providing evidence that the ECV is adequately summarizing the chosen 
external validators.  
2.3.7 Sensitivity Analysis: Demonstrate performance using alternative forms of ECV 
We first recreated the ECV with the mental component QoL validator excluded.  Mental QoL 
was most correlated with the original ECV (𝑐𝑜𝑟𝑟 = 0.615) and so we expected it would create 
the largest change in the ECV when dropped.  Figure 2.17 provides a heatmap of the criteria 
included/excluded among the optimal group of nested subscales using the target ECV with 
mental component QoL excluded.  Using this figure, “Craving” (C4), “Social/interpersonal 
problems” (C6) and “Physical/psychological problems” (C9) are the three criteria included in 
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every subscale and are the same three criteria identified when using the original ECV.  All four 
conceptual domains are also represented in all subscales of size 𝑝 ≥ 4.  However, “Tolerance” 
(C10) is selected for the Pharmacological Indicator domain rather than “Withdrawal” (C11) 
which was selected using the original ECV.  Furthermore, “Used larger amounts/longer” (C1), 
“Activities given up to use” (C7) and “Neglected major roles to use” (C5) are the first three 
criteria to be excluded among the optimal group of nested subscales.  Using the original ECV, 
“Hazardous use” (C8) was the second criteria excluded but when the mental component QoL 
validator was removed from the target ECV, “Hazardous use” (C8) ends up being the fourth 
criteria to be excluded.  While there were minor differences in order, the criteria included in the 
top five most validly ranked criteria and those in the bottom were the same.  
 We further tested the robustness of our methodology by using other various target ECVs 
with certain validators included/excluded and each time we identified the same optimal group of 
nested subscales as was found when using the original ECV.  For example, we recreated ECV 
excluding both history of violence and legal problems and still identified the same nested 
subscales.  Regardless of the validators chosen to be included in the ECV derivation, the 
algorithm still kept at least one criterion from each conceptual domain and found very similar 
results in terms of the optimal group of nested subscales. 
2.3.8 Demonstrate performance of dimensional short-forms identified in NESARC-III on a 
second data source (Wave 2 NESARC) 
The external validators selected to derive ECV in the current drinker Wave 2 NESARC sample 
were the same as the validators selected in NESARC-III (see Table 2.7).  Among the final 
ordered set of optimal dimensional short-forms identified using NESARC-III, we will continue 
our analysis using 𝑝 = 7 and how it performs compared to the DSM-5 AUD Severity in Wave 2 
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NESARC.  In Table 2.8, the 𝑝 = 7 dimensional short-form performs as good at predicting ECV 
(𝑟2 = 0.1690) compared to the DSM-5 AUD Severity rule (𝑟2 = 0.1694).  Furthermore, the 
dimensional short-form is able to distinguish the external validator better than DSM-5 AUD 
Severity for more than half of the possible validators.  Among current drinkers and using the 𝑝 =
7 dimensional short-form, 82.9% were diagnosed as having No Disorder (0 criteria), 13.4% Mild 
AUD (1-2 criteria), 3.1% Moderate AUD (3-5 criteria) and 0.7% Severe AUD (6-7 criteria). 
2.4 DISCUSSION 
Validating the measurement of psychiatric disorders is difficult because there is no gold 
standard. Our data-driven methodology proposes a way to systematically identify valid 
dimensional short-form alternatives to current severity rules using external validators of disorder.  
Identification of external validators to validate diagnoses is not a new concept but using each 
validator separately in the process could prove difficult in determining a consensus across the 
validators.  Our methodology offers a way to combine these external validators into a singular 
summary measure.  Using DSM-5 AUD as an example, we found dimensional short-forms of 
size 𝑝 = 3, 4, . . , 10 that maximally discriminated subjects based on ECV.  The criteria identified 
among these dimensional short-forms ensured that all four conceptual domains were fulfilled 
where “Craving” (C4) was included for Impaired Control, “Social/interpersonal problems” (C6) 
for Social Impairment, “Physical/psychological problems” (C9) for Risky Use and “Withdrawal” 
(C11) for Pharmacological Indicators. 
 We included the full set of 11 criteria into our algorithm and found severity cut-offs that 
performed better at maximally discriminating subjects based on ECV and differed from the 
current DSM-5 AUD severity rule with the following severity categories: None (0 criteria), Mild 
(1-3 criteria), Moderate (4-6 criteria) and Severe (7-11 criteria).  All of the optimally valid 
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severity rules were found to have one single criterion be part of the Mild grouping rather than 
None grouping.  With 𝑝 = 11, this change would lead to 31.6% of persons with disorder, with 
𝑝 = 7 it would be 22.2% compared to DSM-5 which is 19.1%.  Note, though the distinction of 
being Moderate or higher would not be different for the best 𝑝 = 11 rule which also cuts the 
same as DSM with 9.1% grouped as Moderate or Severe.  Based on these findings, we 
recommend this distinction of None requiring 0-1 criteria in the DSM-5 be reconsidered. 
 A key factor in our methodology deals with identifying external validators of disorder to 
derive the ECV.  We chose 11 external validators based on the literature but these came from 
over 40 survey questions which allows for some alteration even within the same type of 
validator.  While there can be adjustments made to which external validators are chosen, the 
specified ones we used provided us consistent criteria selection as shown in our sensitivity 
analysis of using different target ECVs. 
 If the primary goal of the clinician/researcher is to assess trends in terms of what 
combinations of criteria are being selected for the group of nested subscales and severity cut-offs 
that maximize 𝑅2, then a single general population sample is sufficient to find these preliminary 
patterns.  However, if the primary goal is to make recommendations for the use of an alternative 
dimensional short-form, we suggest requiring more than one set of data as well as a clinical 
sample to make such a recommendation. 
 Looking at building upon our methodology, a future direction we are interested in deals 
with incorporating discriminant validation techniques.  Currently, we focus solely on convergent 
validity where optimization is based on maximizing the relationship between subscales and a 
theoretically related construct.  We want to extend this to incorporate discriminant validation by 
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identifying external validators that represent a theoretically dissimilar construct to the current 
disorder and identify subscales that do not correlate with or diverge from the construct. 
 Our proposed methodology provides a systematic way to identify valid dimensional 
short-form alternatives to current severity rules.  The key to our methodology is the construction 
of a single summary measure we call the external composite validator which allows for the 
investigation into patterns of criteria selected and severity cut-offs identified that maximize the 
relationship with the ECV.
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2.5 TABLES AND FIGURES 
Table 2.1 Chosen External Validators for AUD 
External Validator Survey Questions 
Antecedent 
Family history of alcohol 
use 
If answered “yes” to any of the 6 people: Have any of the following 
ever been an alcoholic or problem drinker? 
(1) Blood or natural father 
(2) Blood or natural mother 
(3) Full brother(s) 
(4) Full sister(s) 
(5) Natural son(s) 
(6) Natural daughter(s) 
Early onset of alcohol use 
(<18 years) 
If you first started drinking, not counting small tastes or sips of alcohol 
before 18 years old 
WHO risk level – drinks 
per day (low, medium, 
high, very high) 
The four drinking risk levels were previously constructed by the World 
Health Organization (WHO) and are based on mean ethanol 
consumption (in grams) per day (Hasin et al., 2017)  
History of violence 
If answered “yes” to any of the 9 questions: Have you ever in your 
life... 
(1) Used a weapon like a stick, knife, or gun in a fight? 
(2) Hit someone so hard that you injured them or they had to see a 
doctor? 
(3) Start a fire on purpose to destroy someone else’s property – like 
their car, home, or other personal belongings? 
(4) Force anyone to engage in any sexual activity with you against 
their will? 
(5) Get into physical fights while drinking or right after drinking? 
(6) Get into physical fights while under the influence of a medicine or 
drug? 
(7) Physically hurt another person in any other way on purpose? 
(8) Get into a fight that came to swapping blows with someone like a 
husband, wife, girlfriend or boyfriend? 
(9) Get into a lot of fights that you started? 
Concurrent 
Alcohol treatment 
If answered “yes” to any of the 13 questions: In the last 12 months, 
have you gone to (a/an)... 
(1) Alcoholics Anonymous, Narcotics or Cocaine Anonymous 
meeting, or any 12-step meeting? 
(2) Family service or other social service agency? 
(3) Alcohol or drug detoxification ward or clinic? 
(4) Inpatient ward of a psychiatric or general hospital or community 
mental health program? 
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(5) Outpatient clinic, including outreach programs and day or partial 
patient programs? 
(6) Alcohol or drug rehabilitation program? 
(7) Emergency room for any reason related to your drinking? 
(8) Halfway house, including therapeutic communities? 
(9) Crisis center for any reason related to your drinking? 
(10) Employee assistance program (EAP)? 
(11) Clergyman, priest, rabbi or any other religious counselor for 
any reason related to your drinking? 
(12) Private physician, psychiatrist, psychologist, social worker, or 
any other professional? 
(13) Any other agency or professional? 
Problems with neighbor, 
friend or relative 
If answered “yes” to the following question: During the last 12 
months... 
(1) Have you had serious problems with a neighbor, friend or 
relative? 
Quality of life – mental 
component 
Version 2 of the Short Form 12 Health Survey (SF-12v2) is a 12-item 
measure that assesses life satisfaction and current functioning over the 
most recent four-week period.  These were score to generate norm-
based mental and physical component summary scores (MCS, PCS) 
(Ware et al., 2002).   




If answered “yes” to either: During the last 12 months... 
(1) Were you fired or laid off from a job? 
(2) Were you unemployed and looking for a job for more than a 
month? 
Family income at or below 
HHS poverty level 
At or below the HHS poverty level based on their total combined 
family income received from jobs, businesses, and all other sources. 
Legal problems 
If answered “yes” to any of the 4 questions: During the last 12 months... 
(1) Did you have serious trouble with the police or the law? 
(2) Did any of your family members or close friends have serious 
trouble with the police or the law? 
(3) Did you more than once get arrested, held at a police station or 




    





    




    





Family history of alcohol use 0.408 (0.023) 
Early onset of alcohol use (<18 years) 0.247 (0.024) 
WHO Risk (medium) 0.106 (0.045) 
WHO Risk (high) 0.355 (0.057) 
WHO Risk (very high) 0.863 (0.051) 
History of violence 0.738 (0.026) 
Concurrent/Predictive 
Alcohol treatment 0.647 (0.025) 
Problems with neighbor, friend or relative 0.597 (0.015) 
Quality of life – mental component+ 0.441 (0.009) 
Quality of life – physical component+ 0.123 (0.010) 
Unemployment 0.415 (0.014) 
Family income at or below HHS poverty level 0.343 (0.015) 
Legal problems 0.622 (0.015) 
+ Both QoL measures were reversed coded for consistency (higher values= poorer QoL) 
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Table 2.3 Distribution of ECV by Chosen Demographics in NESARC-III 
Sex Male Female    
      
NESARC-IIIa 50.7% 49.3%    








-1.601 : 4.839 
   
      
p-valuec  0.6566    
      
Age (years) 18 – 24 25 – 44 45 – 64 65+  
      
NESARC-IIIa 14.0% 38.0% 34.7% 13.3%  
















-1.532 : 3.685 
 
      
p-valuec  <0.0001 <0.0001 <0.0001  
















      
NESARC-IIIa 68.5% 10.7% 1.6% 4.9% 14.2% 




















-1.577 : 4.629 
      
p-valuec  <0.0001 <0.0001 <0.0001 0.0006 
      
a Provides weighted % in NESARC-III (n=25,778) sample of current drinkers  
b Provides ECV (n=25,500) n, mean (std), median, min : max 
c Provides p-value from F-Test assessing difference in mean ECV compared to reference group 
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Figure 2.4 Correlation of ECV with External Validators of AUD 
 
* Both QoL measures were reversed coded for consistency and plot provides mean (std) 
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Table 2.4 Total Subsets Possible for DSM-5 AUD 
Size of Criteria Set 
𝒑 
Number of Different 















  a Original, full-length criteria set 
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3 1 1 
4 1 4a 
5 1 10a 
6 1 20 
7 1 35 
8 1 56 
9 1 84 
10 1 120 
11 1 165 
TOTAL 9 495 
a These were used in Figure 2.8 as examples 
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Figure 2.9 R-Squared by Size of Dimensional Short-Form (𝑛 = 495)+ 
 
 +The dimensional short-forms in this figure use criteria from Figure 2.7 
 
 




Figure 2.10 Top Dimensional Short-Forms by Size 𝑝 – R-Squared Predicted by Dimensional Short-forms with Different Severity Cut-
Offs. DSM-5 Severity Rule Included as a Reference+ 
 
+The dimensional short-forms in this figure use criteria from Figure 2.7 
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Figure 2.11 Severity Cut-Offs for Top Performing Dimensional Short-Forms with DSM-5 
Current Severity Rule Included as a Reference+ 
 
+ The dimensional short-forms in this figure use criteria from Figure 2.7 
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Figure 2.13 Severity Cut-Offs for Ordered Set of Optimal Dimensional Short-Forms with DSM-




    






    
Figure 2.15 Mean Difference in R-Squared Among Ordered Set of Optimal Dimensional Short-




    
Figure 2.16 Mean ECV with 95% Confidence Intervals by Severity Category Comparing Best 









Table 2.6 Distribution of External Validators and ECV by Severity Category Comparing DSM-5 AUD Severity and Best 𝑝 = 7 
Dimensional Short-Form 



















DSM-5 Best 𝒑 = 7 
Antecedent 
Family history of 
alcoholism 
41.7% 45.7% 58.5% 65.5% 
 
41.2% 48.2% 60.1% 75.0% 
 
𝑥2 = 371.7 𝒙𝟐 = 416.4 
Early onset of alcohol 
use (<18 years) 
34.2% 50.2% 59.5% 70.1% 
 
33.7% 49.9% 65.0% 77.9% 
 
𝑥2 = 1029.9 𝒙𝟐 = 1101.2 
WHO Risk level           𝑥2 = 7334.2 𝒙𝟐 = 7695.5 
 Low 94.3% 74.8% 55.8% 32.0%  94.3% 77.6% 45.0% 17.1%    
 Medium 3.7% 12.4% 18.0% 15.9%  3.7% 11.0% 18.6% 11.6%    
 High 1.3% 6.5% 12.4% 16.6%  1.3% 5.9% 15.4% 16.9%    
 Very High 0.7% 6.3% 13.8% 35.6%  0.7% 5.6% 21.0% 54.5%    
History of violence 17.8% 32.4% 45.6% 63.0%  16.9% 35.3% 53.9% 70.6%  𝑥2 = 1866.7 𝒙𝟐 = 2074.7 
Concurrent 
Alcohol treatment 0.6% 2.7% 4.9% 21.3%  0.5% 2.7% 9.3% 35.7%  𝑥2 = 2637.3 𝒙𝟐 = 3292.7 
Problems with 
neighbor, friend or 
relative 
6.9% 11.7% 14.8% 22.1% 
 
6.5% 12.9% 18.0% 27.0% 
 
𝑥2 = 442.2 𝒙𝟐 = 554.2 



















𝐹 =341.7 𝑭 = 417.9 



















𝑭 = 29.0 𝐹 = 22.9 
Predictive 
Unemployment 15.7% 24.4% 31.2% 37.0%  15.3% 24.9% 34.6% 39.5%  𝑥2 = 568.8 𝒙𝟐 = 615.9 
Family income at or 
below HHS poverty 
level 
15.9% 18.7% 21.6% 30.5% 
 
15.7% 19.1% 26.9% 32.8% 
 
𝑥2 = 192.5 𝒙𝟐 = 206.7 




















𝑟2 = 0.172 𝒓𝟐 = 0.191 
a Chi-Square (𝑥2) used for categorical validators, ANOVA (F) used for QoL measures and R-Squared (𝑟2) used for ECV 
b Provides mean (std) 
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Figure 2.17 Criteria Included/Excluded in Optimal Group of Nested Subscales using ECV with 




    








Family history of alcohol use N (%) 11,405 (43.9%) 7,772 (34.1%) 
Early onset of alcohol use (<18 years) N (%) 9,478 (38.5%) 6,732 (31.9%) 
WHO risk drinking levels    
 Low  N (%) 22,275 (87.8%) 19,934 (90.1%) 
 Medium N (%) 1,516 (5.7%) 1,162 (5.2%) 
 High N (%) 843 (3.0%) 540 (2.5%) 
 Very High N (%) 1,025 (3.4%) 472 (2.3%) 
History of violence N (%) 5,907 (22.6%) 3,592 (15.7%) 
Any alcohol treatment N (%) 555 (1.9%) 257 (1.1%) 
Problems with neighbors, friends or relatives N (%) 2,328 (8.5%) 1,470 (6.2%) 
    












25.7 : 94.1 
    
    












24.6 : 96.8 
    
    
Unemployed N (%) 5,213 (18.2%) 2,697 (11.8%) 
Family income below HHS poverty level N (%) 5,465 (17.1%) 2,657 (11.2%) 
Legal problems N (%) 2,963 (10.6%) 2,181 (9.4%) 
 
 





Table 2.8 Distribution of External Validators and ECV by Severity Category Comparing DSM-5 AUD Severity and Best 𝑝 =  7 
Dimensional Short-Form in Wave 2 NESARC 



















DSM-5 Best 𝒑 = 7 
Antecedent 
Family history of 
alcoholism 
32.7% 37.5% 44.9% 54.7% 
 
33.1% 36.1% 48.5% 63.9% 
 
𝒙𝟐 = 169.2 𝑥2 = 136.8 
Early onset of alcohol 
use (<18 years) 
28.6% 45.6% 50.6% 60.1% 
 
71.3% 55.6% 44.1% 39.3% 
 
𝒙𝟐 = 615.7 𝑥2 = 535.8 
WHO Risk level           𝑥2 = 5077.1 𝒙𝟐 = 5502.9 
 Low 94.8% 75.4% 58.5% 34.3%  94.4% 77.1% 46.8% 11.3%    
 Medium 3.5% 12.8% 17.3% 14.1%  3.8% 10.8% 16.6% 12.0%    
 High 1.2% 6.9% 12.4% 17.8%  1.3% 6.1% 19.2% 12.9%    
 Very High 0.6% 5.0% 11.9% 33.8%  0.6% 6.1% 17.4% 63.9%    
History of violence 12.5% 25.7% 36.1% 56.0%  12.5% 26.3% 44.1% 75.3%  𝑥2 = 1211.5 𝒙𝟐 = 1215.8 
Concurrent 
Alcohol treatment 0.5% 1.8% 4.5% 13.2%  0.6% 1.9% 6.5% 27.9%  𝑥2 = 862.2 𝒙𝟐 = 1240.7 
Problems with 
neighbor, friend or 
relative 
5.3% 8.5% 11.1% 18.2% 
 
5.3% 8.9% 13.8% 23.5% 
 
𝑥2 = 209.7 𝒙𝟐 = 208.5 



















𝐹 = 277.2 𝑭 = 307.9 



















𝐹 = 10.8 𝑭 = 16.1 
Predictive 
Unemployment 10.0% 17.9% 21.9% 35.1%  9.9% 18.1% 28.8% 39.8%  𝒙𝟐 = 500.0 𝑥2 = 475.5 
Family income at or 
below HHS poverty 
level 
10.2% 15.2% 16.6% 19.8% 
 
9.9% 16.2% 19.9% 22.1% 
 
𝑥2 = 119.7 𝒙𝟐 = 174.2 




















𝒓𝟐 = 0.1694 𝑟2 = 0.1690 
a Chi-Square (𝑥2) used for categorical validators, ANOVA F-Test (F) used for QoL measures and R-Squared (𝑟2) used for ECV 
b Provides mean (std) 
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Chapter 3 
Application to Cannabis and Opioid Use Disorders 
3.1 INTRODUCTION 
Substance use disorders (SUDs) in the DSM-5 include alcohol use disorder (AUD), nicotine use 
disorder (NUD) and drug use disorders (DUDs).  Specific DUDs include sedative/tranquilizer, 
cannabis, amphetamine, cocaine, non-medical prescription opioid, heroin, hallucinogen, club 
drug (e.g., ecstasy, ketamine, and 3,4-methylendioxy-methamphetamine) and solvent/inhalant 
use disorders [Grant et al., 2016].  In the DSM-5, each of these substances is associated with a 
single underlying SUD construct with the same 11 diagnostic criteria used across each substance 
(e.g., “Used larger amounts/longer” (C1), “Repeated attempts to quit/control” (C2), “Tolerance” 
(C10)).  As with AUD, a specific SUD diagnosis is made when two or more of the 11 possible 
criteria are endorsed.  In addition, severity of disorder is the same across all substances with Mild 
SUD requiring the endorsement of 2-3 of these criteria, Moderate SUD requires 4-5 and Severe 
SUD requires 6-11 criteria [APA, 2013; Compton et al., 2013].  
  In previous chapters we used AUD as the example to describe two separate methods for 
identifying and validating diagnostic and dimensional short-forms from the original set of 11 
criteria.  The first method identifies diagnostic short-forms (binary diagnosis; AUD 2+ criteria) 
that act as similar as possible to the current DSM-5 rule.  The second method identifies and 
validates dimensional short-forms (severity of disorder; None (0-1), Mild (2-3), Moderate (4-5), 
Severe (6-11)) using a composite of external validators representing “AUD risks/problems”.  
Since the rest of the SUDs defined in DSM-5 follow the same diagnostic structure as AUD 
[Hasin et al., 2013], it is pertinent to understand how the identified short-forms perform when 
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applied to other substances.  Accordingly, this chapter forward applies the short-forms found for 
AUD to two other commonly used substances: cannabis and non-medical prescription opioids.  
Specifically, we will use data from a nationally representative sample of U.S. adults to assess 
diagnostic accuracy (i.e., sensitivity, specificity) and prevalence estimates as compared to DSM-
5 and assess validity (i.e., correlation, R-Squared with external composite validator) when 
applying AUD short-forms to past-year cannabis users and past-year opioid users. 
 After alcohol and tobacco, cannabis is the most frequently consumed drug with an 
estimated 183 million people having used the drug in 2014 and is the most commonly cultivated, 
trafficked and abused illicit substance worldwide [United Nations Office of Drug Control and 
Crime Prevention (UNODC), 2016; Hayley et al., 2017].  A common assumption about cannabis 
use is that the risk is rare for developing cannabis use disorder (CUD) but recent analyses 
suggest otherwise.  Using U.S. national data, 19.5% of lifetime cannabis users met criteria for 
DSM-5 CUD, of whom 23% were symptomatically severe (6+ criteria).  Furthermore, among 
those diagnosed with Severe CUD, 48% were not functioning in any major role (e.g., work) 
providing evidence that CUD in users is not rare and can be serious [Hasin et al., 2016; Hasin, 
2018]. 
 With an estimated 33 million users, the use of opiates and prescription opioids may not 
be as widespread as the use of cannabis, but opioids remain major drugs of potential harm and 
health consequences [UNODC, 2016; Hayley et al., 2017].  In the U.S., the prevalence of 
prescription opioid use disorder (OUD) increased over the last two decades coinciding with the 
largest epidemic of opioid overdose deaths in US history [Blanco et al., 2007; Han et al., 2015; 
Rudd et al., 2016].  Furthermore, the crisis in nonmedical opioid use has exacted a heavy burden 
on individuals, families and communities which has prompted federal policy makers to consider 
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it a threat to public health [U.S. Department of Health and Human Services (HHS), 2016; Olfson 
et al., 2018). 
 Both cannabis and non-medical opioid use have been identified as major public health 
issues.  Due to their diagnostic similarity to AUD in the DSM-5, these substances are ideal to test 
our methodology.  With the increase in prevalence of CUD and OUD along with the increase in 
awareness across the country, short-forms for assessing these substance use disorders and 
improved validity of the diagnosis itself have high clinical and public health relevance. 
3.2 METHODS 
3.2.1 Data source 
As in Chapters 1 and 2, the data we will use comes from the National Epidemiologic Survey on 
Alcohol and Related Conditions-III (NESARC-III) conducted by the National Institute on 
Alcohol Abuse and Alcoholism (NIAAA) from 2012-2013.  The NESARC-III survey was 
conducted on a nationally representative sample of 36,309 non-institutionalized U.S. civilians 18 
years or older and sampling weights are applied to account for non-response and oversampling 
that occurred among Hispanics, African Americans and Asians [Grant et al., 2014, 2015a].  The 
diagnostic interview was the National Institute on Alcohol Abuse and Alcoholism Alcohol Use 
Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5) [Grant et al., 2015b], 
designed to measure specific DSM-5 DUDs, AUD, NUD and selected mood, anxiety, trauma-
related personality disorders [Grant et al., 2016].   
Participant’s medicine and drug use (including cannabis and opioids) was initiated on the 
survey by stating, “Now I’d like to ask you about your experiences with medicines and other 
kinds of drugs that you may have used ON YOUR OWN – that is, either WITHOUT a doctor’s 
prescription; in GREATER amounts, MORE OFTEN, or LONGER than prescribed; or for a 
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reason other than a doctor said you should use them.”  For cannabis use, participants were asked 
if they had ever used “Mariwa´-na, including THC, for example...weed, pot, dope, hashish, Mary 
Jane, joint, blunt.”  For opioid use, participants were asked if they had ever used “Painkillers, for 
example... methadone, codeine, Demerol, Vy´-ko-din, Oxikon´-tin, opium, oxy, Per´-ko-set, Dill-
odd´-id, Per´-ko-dan, morphine.”  For both cannabis and opioid users, participants were then 
asked their approximate age when the substance was first used and if they had used within the 
past 12 months. 
The 11 criteria for cannabis and opioids are conceptually the same as alcohol (e.g., 
“Tolerance” (C10) is used for all three substances) but there are slight variations in the survey 
questions that are used to derive each criterion for cannabis and opioids compared to alcohol.  
These differences are mainly driven by the fact that it is difficult to quantify drug use relative to 
alcohol use, which can be quantified using recognizable standard units.  For example, an alcohol 
user would have to answer “yes” to any of the four survey questions in the past 12 months to 
have “Tolerance” (C10) endorsed: “Find that your usual number of drinks had much less effect 
on you than it once did?”, “Find that you had to drink much more than you once did to get the 
effect you wanted?”, “Drink as much as a fifth of liquor in one day, that would be about 20 
drinks, or 3 bottles of wine, or as much as 3 six-packs of beer in a single day?”, “Increase your 
drinking because the amount you used to drink didn’t give you the same effect anymore?” (see 
Appendix A).  Whereas, a cannabis/opioid user would have to answer “yes” to either of the two 
questions in the past 12 months to have “Tolerance” (C10) endorsed: “Find that your usual 
amount of [cannabis/opioids] had much less effect on you than it once did?” or “Find that you 
had to use much more of [cannabis/opioids] to get the effect you wanted?” (see Appendix C).  
Appendices A and C have the survey questions in NESARC-III used to derive each criterion for 
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alcohol and cannabis/opioids, respectively.  However, the only difference between the derivation 
of criteria for cannabis and opioids is with the “Withdrawal” (C11) criterion as seen in Appendix 
D (see Table D.1 for cannabis withdrawal and Table D.2 for opioid withdrawal). 
As with AUD, diagnosis of current DSM-5 CUD and OUD requires at least two of the 11 
diagnostic criteria within the 12-month period [APA, 2013; Hayley et al., 2017].  Psychometric 
assessment of reliability of current diagnoses of drug use disorders (including CUD and OUD) 
have been shown to be good to excellent when evaluated in a general population sample [Grant 
et al., 2015b; Hayley et al., 2017].  The analysis was restricted to past-year users of alcohol (𝑛 =
25,778), cannabis (𝑛 = 3,701) and opioids (𝑛 = 1,579). 
3.2.2 Do AUD diagnostic short-forms that accurately replicate DSM-5 AUD work just as well 
for CUD and OUD? 
Previously (Chapter 1) we systematically identified subsets of the original AUD criteria and 
associated cut-offs (i.e., diagnostic short-forms) that yielded diagnoses as similar as possible to 
using all criteria for AUD by:  (1) maximizing the association between the sum scores of all 11 
criteria with newly constructed subscales from subsets of criteria, (2) optimizing the similarity of 
AUD prevalence between the current DSM-5 rule and newly constructed diagnostic short-forms, 
(3) maximizing sensitivity and specificity of the short-forms against the current DSM-5 rule, and 
(4) minimizing differences in the accuracy of the short-form across chosen covariates.   
Among over 11,000 possible diagnostic short-forms that can be constructed from the 11 
diagnostic criteria, our method identified eight top performing diagnostic short-forms for AUD 
of size 𝑝 = 4, 7, 8, 9, 10.  Among these top performers, two rules were each identified of size 
𝑝 = 4 and 10 but none were selected for size 𝑝 = 5, 6.  For the present application to other 
substances, we expanded the list of optimal diagnostic short-form for each size 𝑝, where 𝑝 =
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4, 5, 6, 7, 8, 9, 10 (Table 3.3).  We did this by opening up the algorithm to remove the last 
screening step (Step 7: Differential Test Functioning) that originally screened out the 𝑝 = 5 and 
6 diagnostic short-forms.  Once this step was removed, we took the top performing diagnostic 
short-form of size 𝑝 = 5 and 6 in terms of sensitivity and specificity.  Each of the seven 
diagnostic short-forms are applied to current users of cannabis and current users of opioids to 
assess the diagnostic accuracy of each substance’s diagnostic short-forms compared to their 
respective DSM-5 SUD rule.  In addition to forward applying, we also re-ran our algorithm for 
each substance separately to compare the diagnostic short-forms identified across substances. 
3.2.3 Do the most valid dimensional short-form criteria for AUD work with high validity for 
CUD and OUD? 
Identifying a shorter criteria set that replicates DSM-5 severity may not be the most desirable 
goal if there is uncertainty about the validity of the severity cut-offs of DSM-5.  Previously 
(Chapter 2) we developed a method that systematically identified and validated subsets and 
associated severity cut-offs (i.e., dimensional short-forms) that were most related to a composite 
of external validators of AUD.  We did this by first identifying antecedent, concurrent and 
predictive external validators of AUD.  Then, a multiple indicator multiple cause (MIMIC) latent 
factor model was fit to all external validators with antecedent validators as risks (or “causes”) of 
the latent composite validator and concurrent and predictive validators as consequences (or 
“indicators”) of the latent composite validator.  After assessing model fit, we extracted and 
standardized the factor score to derive a final external composite validator (ECV) representing 
“AUD risks/problems”.  Following principles of convergent validity, we found dimensional 
short-forms that were most strongly related to the ECV.  Specifically, we obtain nested subsets 
of the original criteria set that (1) maximized the association between ECV and newly 
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constructed subscales from subsets of criteria and (2) obtained associated severity cut-offs that 
maximally discriminated on ECV based on R-Squared (𝑅2). 
 Our methodology identified nine top performing dimensional short-forms for AUD with 
one identified for each size of 𝑝, where 𝑝 = 3, 4, … , 11 (Table 3.5).  The 𝑝 = 11 severity rule is 
an alternative to the current DSM-5 severity rule in terms of the criteria required for entry into 
each severity category.  To assess the most valid rules found for AUD to CUD and OUD, we 
must identify antecedent, concurrent and predictive external validators separately for cannabis 
and opioids (Table 3.1).  Then, using the same MIMIC method we derive an ECV for each 
substance representing “CUD risks/problems” and “OUD risks/problems”.  Using the ECV, we 
assess the performance (i.e., correlation and 𝑅2) of each of the nine dimensional short-forms 
identified using AUD as applied to cannabis and opioids.  In addition, using 𝑅2 and 95% 
confidence intervals we can determine whether the dimensional short-forms are significantly 
different in terms of predicting ECV compared to each substance’s DSM-5 severity rule.  If a 
dimensional short-form is found to be significantly better at predicting ECV than the current 
severity rule, this builds evidence for the case that the dimensional short-form is a more valid 
measure of disorder severity.  Furthermore, we unpack the ECV for each substance and assess 
the performance of the 𝑝 = 7 dimensional short-form against each individual external validator 
as compared to using the current DSM-5 severity rule.  Lastly, in addition to forward applying 
the AUD dimensional short-forms to CUD and OUD, we also implemented our validity 






    
3.3 RESULTS 
3.3.1 Cannabis and opioid use disorders in NESARC-III 
Table 3.2 provides the breakdown of current users among the three substances (alcohol, cannabis 
and opioids).  There were 𝑛 = 26,259 participants with at least one current user status among 
the substances with 2.1% being a current user for all three substances.  Figure 3.1 provides the 
prevalence of the 11 criteria among current users and each substance has a different most 
prevalent criterion with “Used larger amounts/longer” (C1) for alcohol (14.7%), “Hazardous 
use” (C8) for cannabis (24.6%) and “Tolerance” (C10) for opioids (18.0%).  Using the DSM-5 
definition of two of more of the 11 criteria, 19.1% of current drinkers were diagnosed with AUD, 
26.8% of cannabis users were diagnosed with CUD and 21.9% of opioid users were diagnosed 
with OUD. 
3.3.2 Forward apply diagnostic short-forms found to accurately replicate DSM-5 AUD to CUD 
and OUD 
Table 3.3 provides the performance of the top performing diagnostic short-forms from AUD as 
applied to current users of cannabis and current users of opioids.  For each substance, the 
diagnostic short-forms ranging in size from 𝑝 = 4 to 10 were compared to each substance’s 
respective DSM-5 rule and Table 3.3 provides diagnostic accuracy measures (sensitivity, 
specificity) along with prevalence estimates.   
The recommended optimization criteria (Chapter 1) were to require the diagnostic short-
forms to maintain a prevalence within  5% of the current AUD DSM-5 rule and estimates of 
sensitivity and specificity ≥ 0.90.  Using these recommendations when applied to current opioid 
users, all seven diagnostic short-forms were found to be within five percent of the 21.9% of 
current users diagnosed with OUD and all estimates of diagnostic accuracy (including 95% 
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confidence intervals) were greater than 0.90.  For cannabis, five of the seven diagnostic short-
forms were found to be within five percent of the 26.8% diagnosed with CUD using the current 
rule with sensitivity and specificity estimates greater than 0.90.  The 𝑝 = 4 diagnostic short-form 
under-diagnosed CUD (14.6%) and consequently had sensitivity estimates less than 0.90 (𝑆𝑒 =
0.547; 95% CI: 0.508, 0.586) while the 𝑝 = 6 diagnostic short-form was within the 
recommended prevalence (23.1%) but underperformed in terms of sensitivity (𝑆𝑒 = 0.861; 95% 
CI: 0.835, 0.888).   
 We applied our step-by-step data driven method to CUD and OUD and Table 3.3 
indicates whether the seven diagnostic short-forms found for AUD would have been chosen for 
CUD and OUD or else would have been screened out.  For cannabis, the short-forms of size 𝑝 ≥
7 are chosen by our method for CUD while those found for AUD of size 𝑝 = 4, 5 were screened 
out for CUD at the correlation screening step (Step 3) and the 𝑝 = 6 diagnostic short-form found 
for AUD was excluded for CUD at the sensitivity/specificity screening step (Step 6).  For 
opioids, all of the short-forms found for AUD were also identified for OUD except for the 𝑝 = 5 
diagnostic short-form being excluded at the correlation screening step (Step 3).   
 We note that while the 𝑝 = 7 and 8 diagnostic short-forms for AUD also are chosen for 
cannabis and opioids, for alcohol, 𝑝 = 7, 8 had sensitivity ≥ 0.953 but dropped to 0.898 and 
0.887 for cannabis and opioids, respectively.  Focusing on the diagnostic short-forms of size 𝑝 =
9, 10, we see that excluding “Neglected major roles to use” (C5) and/or “Activities given up to 






    
3.3.3 Forward apply most valid dimensional short-forms for AUD to CUD and OUD 
We identified similar external validators for cannabis and opioids as were selected for alcohol 
(Table 3.1) but substituting questions about the respective drug when appropriate (e.g., treatment 
for opioids, age at first use of cannabis).  Table 3.4 provides the external validators used to 
construct the ECV across the three substances.  Using all 11 external validators identified in 
Table 3.1, ECV was derived for 99.2% (𝑛 = 3,673) of current cannabis users after finding good 
model fit by RMSEA ≤ 0.06 (RMSEA=0.024) and CFI ≥ 0.90 (CFI=0.922) [Hu and Bentler, 
1999] from a 1-factor model.  Missing ECV occurs if a participant is missing data for any one of 
the antecedent validators and we recommend imputing missing values if the proportion missing 
exceeds 5% [Graham and Hofer, 2000].  Figure 3.2 provides the distribution of ECV after 
standardization where values range from -2.04 to 3.24 with higher values representing worse 
“CUD risks/problems”. 
The derivation of ECV for opioid users was slightly different from alcohol and cannabis.  
A single factor model for all 11 external validators did not fit well (RMSEA=0.076, CFI=0.516).  
To investigate the reason for the poor fit, an exploratory factor analysis (EFA) was performed 
and found evidence of a second underlying factor related to physical QoL and frequency of 
opioid use separate from the first underlying factor using the rest of the external validators that 
represent “OUD risks/problems”.  After refitting the model excluding physical QoL and 
frequency of use, we found good model fit (RMSEA=0.025, CFI=0.943)] from a 1-factor model 
and derived ECV for 99.5% (𝑛 = 1,571) of current opioid users.  Figure 3.3 provides the 
distribution of “OUD risks/problems” with values ranging from -1.83 to 3.18 (higher values 
represent worse “OUD risks/problems”). 
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 Table 3.5 provides the performance of the top dimensional short-forms from AUD as 
applied to current users of cannabis and current users of opioids (DSM-5 rule included as 
reference).  Using each substance’s respective ECV, we obtained 𝑅2 estimates with 95% 
confidence intervals for each dimensional short-form.  Figure 3.4 provides the test of the 
difference in  𝑅2 between each dimensional short-form and the respective DSM-5 severity rule 
(“DMS-5” label).  For alcohol, as previously shown, all of the most valid dimensional short-
forms that were identified, except for 𝑝 = 3, were significantly better predictors of ECV than 
DSM-5 and hence more valid measures of AUD severity.  For both cannabis and opioids, the 
dimensional short-forms and severity cut-offs chosen for AUD with 𝑝 ≥ 5 criteria were found to 
have similar (non-inferior) association with their respective ECVs as the DSM-5 CUD and OUD 
but were not found to be significantly better. 
 Tables 3.4 and 3.5 compare DSM-5 severity to the non-inferior 𝑝 = 7 dimensional short-
form for each external validator for cannabis (Table 3.4) and opioids (Table 3.5).  For cannabis, 
the 𝑝 = 7 dimensional short-form is able to maximally discriminate eight of the 11 external 
validators better than the DSM-5 severity rule and for opioids, this was found for five of the nine 
external validators, providing additional evidence for the validity of the dimensional short-form 
and demonstrates the ECV is adequately summarizing the chosen external validators. 
 Forward applying the dimensional short-forms identified with alcohol to cannabis and 
opioids failed to provide evidence of a more valid rule compared to the substance’s respective 
current DSM-5 severity rule.  To investigate this further, we re-ran our methodology for each 
substance to identify each substance’s unique set of nested subscales and ordered set of 
dimensional short-forms.  Tables 3.8 and 3.9 provide the criteria included/excluded of the set of 
nested subscales and severity cut-offs of the optimal dimensional short-forms for all three 
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substances, respectively.  Figure 3.5 provides the mean difference in  𝑅2 among the ordered set 
of optimal dimensional short-forms for cannabis.  The method found dimensional short-forms of 
size 𝑝 ≥ 9 are significantly better predictors of ECV compared to DSM-5 severity and hence, 
more valid measures of CUD severity.  We can compare the criteria selected and severity cut-
offs chosen for cannabis and alcohol to understand why the dimensional short-forms for alcohol 
did not perform as well with cannabis.  In terms of criteria selected to be included/excluded, 
there are only slight differences in the 𝑝 ≥ 9 dimensional short-forms between alcohol and 
cannabis with both dropping “Used larger amounts/longer” (C1) while alcohol additionally drops 
“Hazardous use” (C8) and cannabis additionally drops “Repeated attempts to quit/control” (C2) 
(see Table 3.8).  Looking at the severity cut-offs chosen in Table 3.9 between alcohol and 
cannabis, the None and Severe groups are very similar for both substances in terms of the 
number of criteria required for a categorization.  Specifically, both alcohol and cannabis require 
zero criteria for a None categorization and both require 7-11 criteria when 𝑝 = 11, 6-10 criteria 
when 𝑝 = 10 and either 6-9 criteria for alcohol or 5-9 criteria for cannabis when 𝑝 = 9 for a 
Severe categorization.  The main difference between the dimensional short-forms deals with the 
Mild and Moderate severity categories where the severity cut-offs chosen require less criteria for 
a Moderate categorization for cannabis compared to alcohol.  Specifically, cannabis requires at 
least two criteria present for a Moderate categorization compared to three or four criteria for 
alcohol. 
 Figure 3.4 provides mean difference in 𝑅2 among the ordered set of optimal dimensional 
short-forms for opioids when compared to DSM-5 OUD severity.  Forward application of AUD 
rules to opioids found that none of the dimensional short-forms were found to be significantly 
better predictors of ECV compared to the current DSM-5 OUD severity rule.  However, after re-
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running our method on opioids separately, we identified a set of optimal dimensional short-forms 
of size 𝑝 ≥ 7 that are significantly better predictors of ECV (Figure 3.4).  Comparing the 𝑝 ≥
7 dimensional short-forms identified from alcohol and opioids separately, there are slight 
variations in the criteria selected to be included/excluded in the nested set of subscales (Table 
3.8).  Among the first four criteria selected to be excluded for alcohol and opioids, both exclude 
“Used larger amounts/longer” (C1) and “Activities given up to use” (C7) while alcohol then 
additionally drops “Repeated attempts to quit/control” (C2) and “Hazardous use” (C8) and 
opioids additional drops “Much time spent using” (C3) and “Withdrawal” (C11).  Beside the 
None category where both substances require zero criteria, the severity cut-offs chosen were 
substantially different for Mild, Moderate and Severe across the two substances.  Specifically, 
opioids require high symptom counts for a Severe categorization compared to alcohol.  For 
example, when 𝑝 = 11, opioids require 10-11 criteria while alcohol requires 7-11 criteria and 
when 𝑝 = 10, opioids require 9-10 criteria while alcohol requires 6-10 criteria.  Furthermore, 
opioids have more spread in terms of criteria required for a Mild categorization than compared to 
alcohol.  For example, when 𝑝 = 11 a participant with five criteria endorsed would be 
categorized as Mild OUD (1-5 criteria) while five criteria for alcohol would categorize a 
participant with Moderate AUD (4-5 criteria).  Based on our investigation, a combination of 
criteria selected to be included/excluded and severity-cuts chosen are both driving factors in the 
differences between dimensional short-forms identified for opioids compared to those identified 
for alcohol and applied to opioids. 
3.4 DISCUSSION 
In previous chapters, we proposed two methods to identify and validate short-forms of full-
length criteria sets and used DSM-5 AUD to describe each of our methods.  After we identified 
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diagnostic short-forms for AUD in Chapter 1 and identified and validated dimensional short-
forms for AUD in Chapter 2, we forward applied these top performers to current users of 
cannabis and opioids in the current Chapter.  Since all DSM-5 SUDs follow the same diagnostic 
structure with 11 criteria, each have binary rules requiring two or more for a diagnosis of 
disorder and each have a severity structure of None (0-1 criteria), Mild (2-3 criteria), Moderate 
(4-5 criteria) and Severe (6-11 criteria), it is important to determine if rules found for one 
substance could be applied to other substances. 
 Forward applying the top performing diagnostic short-forms found to accurately replicate 
DSM-5 AUD to CUD and OUD, we found excluding “Neglected major roles to use” (C5) and 
“Activities given up to use” (C7) provided mean estimates of sensitivity ≥ 0.985 and specificity 
= 1.00.  Dropping these two criteria across substances maintained high diagnostic accuracy with 
each substance’s current DSM-5 rule and maintained prevalence of disorder within 5%.  In 
addition, we re-ran our algorithm to identify diagnostic short-forms for each substance separately 
and each substance identified the same diagnostic short-forms of size 𝑝 ≥ 7. 
 Forward applying the most valid dimensional short-forms for AUD to CUD and OUD, 
none were found to be statistically better at predicting ECV than each substance’s current DSM-
5 severity rule.  To investigate why the AUD severity rules were ineffective in their application 
to cannabis and opioids, we applied our methodology on each substance separately.  Overall, we 
found that a combination of the criteria selected to be included/excluded in the optimal set of 
nested subscales and the severity cut-offs chosen were part of the reason the dimensional short-
forms identified for alcohol underperformed when applied to cannabis and opioids.  When 
identifying dimensional short-forms for each substance separately, three dimensional short-forms 
of size 𝑝 ≥ 9 for cannabis and five dimensional short-forms of size 𝑝 ≥ 7 for opioids were found 
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to be statistically better at predicting ECV and hence build the case for more valid measures of 
disorder severity.  Further, each maintained at least one criterion from each of the four 
conceptual domains (Impaired Control, Social Impairment, Risky Use and Pharmacological). 
We found different severity cut-points provided the best validity with the full 𝑝 = 11 
criteria for each substance and compared to DSM-5.  Specifically, alcohol found severity cut-offs 
of None (0 criteria), Mild (1-3 criteria), Moderate (4-6) and Severe (7-11) had a higher mean 
difference in 𝑟2 of 0.0162 (95% CI: 0.003, 0.011) between the severity rule and the current 
DSM-5 AUD severity rule.  For cannabis, changing the severity cut-offs to None (0 criteria), 
Mild (1 criteria), Moderate (2-6 criteria) and Severe (7-11 criteria) provided a higher mean 
difference in 𝑟2 of 0.011 (95% CI: 0.002, 0.021) while opioids found changing to None (0 
criteria), Mild (1-5 criteria), Moderate (6-9 criteria) and Severe (10-11 criteria) also provided a 
higher mean difference of 0.028 (95% CI: 0.004, 0.052). 
A reason for the differences, especially for the OUD severity cut-offs, may be due to the 
derivation of the final ECV for OUD which did not address chronic pain.  Specifically, in 2013, 
several review papers [Hojsted and Sjogren, 2007; Minozzi et al., 2013; Vowles et al., 2015] 
reported widely diverging rates (from 0% to over 50%) of opioid addiction among non-
malignant pain patients prescribed opioids to treat chronic pain [Hojsted and Sjogren, 2007].  
These differences were mainly driven by the variation in the methods used to assess addiction 
[Hojsted and Sjogren, 2007; Minozzi et al., 2013; Vowles et al., 2015] and made it evident that 
the diagnosis of addiction among chronic pain patients is difficult using the 11 DSM-5 OUD 
criteria [Hojsted and Sjogren, 2007].  OUD is an emerging epidemic and research is ongoing so 
as advances are made, additional adjustments may be necessary in the derivation of the ECV to 
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account for issues like chronic pain as well as identification of more optimal external validators 
for OUD in addition to any adjustments that may be made to the DSM OUD criteria. 
Most of the evidence for the current severity cut-off structure (i.e., None (0-1), Mild (2-
3), Moderate (4-5), Severe (6-11) is based on expert discussions and panels conducted by the 
DSM-5 Substance-Related Disorders Work Group.  While expert opinion is often the best 
approach in this type of setting, we offer an empirical argument to reconsider the current cut-offs 




    
3.5 TABLES AND FIGURES 
Table 3.1 Chosen External Validators for Cannabis and Opioids 
External Validator Survey Questions 
Antecedent 
Family history of drug use 
If answered “yes” to any of the 6 people: Have any of the following 
ever had a drug problem? 
(7) Blood or natural father 
(8) Blood or natural mother 
(9) Full brother(s) 
(10) Full sister(s) 
(11) Natural son(s) 
(12) Natural daughter(s) 
Early onset of cannabis / 
opioid use (<18 years) 
 
If you first started using cannabis / opioids, before 18 years old 
Frequency of cannabis / 
opioid usea 
Frequency of use was assessed with an 11-level item ranging from no 
use in the past 12 months to use every day in the past 12 months. 
History of violence 
If answered “yes” to any of the 9 questions: Have you ever in your 
life... 
(10) Used a weapon like a stick, knife, or gun in a fight? 
(11) Hit someone so hard that you injured them or they had to see a 
doctor? 
(12) Start a fire on purpose to destroy someone else’s property – 
like their car, home, or other personal belongings? 
(13) Force anyone to engage in any sexual activity with you against 
their will? 
(14) Get into physical fights while drinking or right after drinking? 
(15) Get into physical fights while under the influence of a 
medicine or drug? 
(16) Physically hurt another person in any other way on purpose? 
(17) Get into a fight that came to swapping blows with someone 
like a husband, wife, girlfriend or boyfriend? 
(18) Get into a lot of fights that you started? 
Concurrent 
Cannabis / Opioid treatment 
If answered “yes” to any of the 14 questions: In the last 12 months for 
cannabis / opioids, have you gone to (a/an)... 
(14) Alcoholics Anonymous, Narcotics or Cocaine Anonymous 
meeting, or any 12-step meeting? 
(15) Family service or other social service agency?  
(16) Alcohol or drug detoxification ward or clinic?  
(17) Inpatient ward of a psychiatric or general hospital or 
community mental health program?  
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(18) Outpatient clinic, including outreach programs and day or 
partial patient programs?  
(19) Drug or alcohol rehabilitation program? 
(20) Methadone maintenance program?  
(21) Emergency room for any reason related to drug use? 
(22) Halfway house, including therapeutic communities? 
(23) Crisis center for any reason related to drug use?  
(24) Employee assistance program (EAP)?  
(25) Clergyman, priest, rabbi or any other religious counselor for 
any reason related to drug use?  
(26) Private physician, psychiatrist, psychologist, social worker, or 
any other professional?  
(27) Any other agency or professional?  
Problems with neighbor, friend 
or relative 
If answered “yes” to the following question: During the last 12 
months... 
(2) Have you had serious problems with a neighbor, friend or 
relative? 
Quality of life – mental 
component 
Version 2 of the Short Form 12 Health Survey (SF-12v2) is a 12-item 
measure that assesses life satisfaction and current functioning over the 
most recent four-week period.  These were score to generate norm-
based mental and physical component summary scores (MCS, PCS) 
[Ware et al., 2002].   




If answered “yes” to either: During the last 12 months... 
(3) Were you fired or laid off from a job? 
(4) Were you unemployed and looking for a job for more than a 
month? 
Family income at or below 
HHS poverty level 
At or below the HHS poverty level based on their total combined 
family income received from jobs, businesses, and all other sources. 
Legal problems 
If answered “yes” to any of the 4 questions: During the last 12 
months... 
(4) Did you have serious trouble with the police or the law? 
(5) Did any of your family members or close friends have serious 
trouble with the police or the law? 
(6) Did you more than once get arrested, held at a police station or 
have any other legal problems because of your medicine or drug 
use? 
a External validator only used for cannabis (not used for opioids)  
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Table 3.2 Current Drinkers and Current Users in NESARC-III 
Current 
Drinkers 
(𝒏 = 𝟐𝟓, 𝟕𝟕𝟖) 
Current 
Cannabis Users 
(𝒏 = 𝟑, 𝟕𝟎𝟏) 
Current Opioid 
Users 
𝒏 = 𝟏, 𝟓𝟕𝟗 
Total 
No 
No Yes 240 (0.8%) 
Yes 
No 206 (0.6%) 
Yes 35 (0.1%) 
Yes 
No 
No 21,598 (83.8%) 
Yes 720 (2.5%) 
Yes 
No 2,876 (10.1%) 
Yes 584 (2.1%) 
Total   26,259 
 
 









    
Table 3.3 Descriptive Summaries for Top Performing Diagnostic Short-Forms Identified with 















21.9% DSM-5 OUD 




Prevalence  0.191 (0.185, 0.196) 0.267 (0.248, 0.285) 0.219 (0.196, 0.242) 
Sensitivity 0.998 (0.997, 0.999) 0.996 (0.991, 0.100) 0.999 (0.997, 0.100) 
Specificity  1.00 1.00 1.00 




Prevalence 0.190 (0.185, 0.196) 0.265 (0.247, 0.284) 0.216 (0.192, 0.239) 
Sensitivity 0.996 (0.995, 0.998) 0.991 (0.983, 0.999) 0.985 (0.972, 0.995) 
Specificity  1.00 1.00 1.00 
Step Excluded Final Final Final 
8 2 
Excludes: 
C3, C5, C7 
Prevalence  0.188 (0.183, 0.194) 0.250 (0.232, 0.268) 0.200 (0.178, 0.222) 
Sensitivity 0.986 (0.982, 0.990) 0.933 (0.915, 0.950) 0.914 (0.877, 0.952) 
Specificity  1.00 1.00 1.00 
Step Excluded Final Final Final 
7 2 
Excludes: 
C3, C5, C6, 
C7 
Prevalence  0.182 (0.176, 0.188) 0.240 (0.222, 0.258) 0.194 (0.172, 0.216) 
Sensitivity 0.953 (0.946, 0.960) 0.898 (0.875, 0.921) 0.887 (0.848, 0.926) 
Specificity  1.00 1.00 1.00 
Step Excluded Final Final Final 
6a 2 
Excludes: 
C3, C5, C6, 
C7, C9 
Prevalence  0.176 (0.170, 0.181) 0.231 (0.213, 0.248) 0.189 (0.167, 0.212) 
Sensitivity 0.919 (0.909, 0.929) 0.861 (0.835, 0.888) 0.866 (0.824, 0.907) 
Specificity  1.00 1.00 1.00 
Step Excluded STEP 7: DTF STEP 6: SeSp Final 
5a 1 
Excludes: 
C2, C3, C5, 
C7, C8, 
C11 
Prevalence  0.239 (0.233, 0.245) 0.295 (0.277, 0.313) 0.253 (0.226, 0.280) 
Sensitivity 0.953 (0.945, 0.960) 0.889 (0.863, 0.914) 0.866 (0.819, 0.912) 
Specificity  0.929 (0.925, 0.933) 0.922 (0.908, 0.936) 0.919 (0.899, 0.938) 
Step Excluded STEP 7: DTF STEP 3: Corr STEP 3: Corr 
4 1 
Excludes: 
C1, C3, C4, 
C5, C6, C7, 
C10 
Prevalence  0.246 (0.239, 0.253) 0.146 (0.131, 0.161) 0.281 (0.259, 0.302) 
Sensitivity 0.921 (0.913, 0.929) 0.547 (0.508, 0.586) 0.958 (0.928, 0.988) 
Specificity  0.913 (0.908, 0.918) 1.00 0.909 (0.892, 0.927) 
Step Excluded Final STEP 3: Corr  Final 




    
Table 3.4 External Validators Used in Each Substance’s ECV 
External Validator Alcohol Cannabis Opioids 
Antecedent    
Family history of:    
 Alcohol use x   
 Any drug use  x x 
Early onset of (<18 years):    
 Alcohol use x   
 Cannabis use  x  
 Opioid use   x 
WHO Risk Level (drinks per drinking day) x   
Frequency of:    
 Cannabis use  x  
 Opioid usea   x 
History of violence x x x 
Concurrent    
Treatment for:    
 Alcohol use x   
 Cannabis use  x  
 Opioid use   x 
Problems with neighbor, friend or relative x x x 
Mental QoL x x x 
Physical QoLa x x x 
Predictive    
Unemployment x x x 
Family income at or below HHS poverty level x x x 
Legal problems x x x 
a External validator excluded from ECV for opioids 
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Figure 3.3 Distribution of ECV Among Current Non-Medical Users of  




    
Table 3.5 Descriptive for Top Performing Dimensional Short-Forms Identified with AUD 


















































Kappa with DSM 0.7779 0.7342 0.7879 
Correlation with ECVa 0.4410 0.3670 0.3435 




















Kappa with Best p=11 0.9420 0.9250 0.9446 
Correlation with ECVa 0.4445 0.3705 0.3439 




















Kappa with Best p=11 0.8823 0.8678 0.9238 
Correlation with ECVa 0.4447 0.3597 0.3386 





















Kappa with Best p=11 0.8785 0.8618 0.9147 
Correlation with ECVa 0.4437 0.3604 0.3404 





















Kappa with Best p=11 0.7732 0.7547 0.8400 
Correlation with ECVa 0.4413 0.3657 0.3407 






















Kappa with Best p=11 0.7604 0.7069 0.7948 
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Correlation with ECVa 0.4393 0.3553 0.3462 






















Kappa with Best p=11 0.7763 0.7248 0.7938 
Correlation with ECVa 0. 4353 0.3512 0.3378 























Kappa with Best p=11 0.7107 0.6390 0.6880 
Correlation with ECVa 0.4294 0.3277 0.3286 























Kappa with Best p=11 0.6186 0.5776 0.5597 
Correlation with ECVa 0.4202 0.3153 0.3243 
R-Squared 0.178 (0.166, 0.190) 0.102 (0.081, 0.124) 0.109 (0.073, 0.145) 
a Correlation between subscale (sum count of criteria) and ECV 
 
 





Figure 3.4 Mean Difference in R-Squared Among Ordered Set of Optimal Dimensional Short-Forms Identified with AUD Applied to 









Table 3.6 Distribution of Cannabis External Validators and ECV by Severity Category Comparing DSM-5 CUD Severity and Best 
𝑝 = 7 Dimensional Short-Form 



















DSM-5 Best 𝒑 = 7 
Antecedent 
Family history of 
drug use 
39.9% 48.6% 51.8% 56.9% 
 
39.4% 47.0% 54.9% 64.4% 
 
𝑥2 =  42.1 𝒙𝟐 = 49.8 
Early onset of 
marijuana use (<18 
years) 
64.4% 76.8% 74.2% 83.0% 
 
64.3% 73.2% 79.8% 82.2% 
 
𝒙𝟐 = 𝟔𝟐. 𝟒 𝑥2 = 53.2 


















𝑥2 =  236.4 𝒙𝟐 = 245.6 
History of violence 42.5% 57.2% 58.4% 66.1%  41.8% 55.1% 63.7% 62.1%  𝑥2 = 89.1 𝒙𝟐 = 91.6 
Concurrent 
Marijuana treatment 1.2% 4.7% 6.4% 17.4%  1.2% 3.5% 12.0% 17.1%  𝒙𝟐 = 204.7 𝑥2 = 165.7 
Problems with 
neighbor, friend or 
relative 
13.5% 22.3% 24.4% 29.3% 
 
13.3% 20.3% 26.5% 35.2% 
 
𝑥2 = 68.4 𝒙𝟐 = 69.0 



















𝐹 = 26.9 𝑭 = 35.2 



















𝐹 = 1.6  𝑭 = 3.30 
Predictive 
Unemployment 32.1% 41.4% 47.6% 54.2%  31.6% 40.3% 51.1% 60.5%  𝑥2 = 70.0 𝒙𝟐 = 77.4 
Family income at or 
below HHS poverty 
level 
27.6% 33.6% 38.8% 47.3% 
 
27.2% 32.3% 44.4% 54.7% 
 
𝑥2 = 50.2 𝒙𝟐 = 62.6 




















𝑟2 = 0.130  𝒓𝟐 = 𝟎. 𝟏𝟑𝟓 
a Chi-Square (𝑥2) used for categorical validators, ANOVA (F) used for QoL measures and R-Squared (𝑟2) used for ECV 










Table 3.7 Distribution of Opioid External Validators and ECV by Severity Category Comparing DSM-5 OUD Severity and Best 𝑝 =
 7 Dimensional Short-Form 



















DSM-5 Best 𝒑 = 7 
Antecedent 
Family history of drug 
use 
40.8% 50.7% 54.7% 61.3% 
 
40.2% 49.4% 54.1% 73.3% 
 
𝑥2 =  24.2 𝒙𝟐 = 29.9 
Early onset of opioid 
use (<18 years) 
23.3% 21.2% 25.4% 41.7% 
 
22.5% 26.7% 34.2% 33.4% 
 
𝒙𝟐 = 𝟏𝟖. 𝟗 𝑥2 = 11.0 
History of violence 41.7% 58.9% 50.1% 75.8%  41.5% 51.9% 65.7% 78.3%  𝒙𝟐 = 58.4 𝑥2 = 49.4 
 
Opioid treatment 2.1% 4.7% 13.1% 41.1%  2.0% 5.3% 23.8% 47.9%  𝒙𝟐 = 296.4 𝑥2 = 253.4 
Problems with 
neighbor, friend or 
relative 
14.0% 21.0% 19.3% 37.8% 
 
13.1% 21.4% 26.4% 48.2% 
 
𝑥2 = 43.5 𝒙𝟐 = 𝟓𝟒. 𝟖 



















𝐹 = 40.2 𝑭 = 49.9 
 
Unemployment 29.4% 38.1% 24.8% 40.8%  28.9% 35.2% 27.4% 62.3%  𝑥2 = 11.5 𝒙𝟐 = 25.7 
Family income at or 
below HHS poverty 
level 
27.5% 37.8% 31.3% 39.9% 
 
27.5% 32.0% 39.1% 42.2% 
 
𝑥2 = 10.4 𝒙𝟐 = 11.4 




















𝑟2 = 0.104 𝒓𝟐 = 𝟎. 𝟏𝟎𝟖 
a Chi-Square (𝑥2) used for categorical validators, ANOVA (F) used for QoL measures and R-Squared (𝑟2) used for ECV 
b Provides mean (std) 
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Table 3.8 Criteria Included/Excluded in Optimal Group of Nested Subscales Identified for 
Alcohol, Cannabis and Opioids by Conceptual Domainab 




















10 1 2 3 4  5 6 7 8 9 10 11 1 2 3 4  5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
9 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
8 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
7 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
6 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
5 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
4 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
3 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 
a Conceptual Domains: Impaired Control (C1-C4), Social Impairment (C5-C7), Risky Use (C8,C9) and 
Pharmacological Indicators (C10, C11) 
b Criteria: C1=Used larger amounts/longer, C2=Repeated attempts to quit/control, C3=Much time spent 
using, C4=Craving, C5=Neglected major roles to use, C6=Social/interpersonal problems, 




    
Table 3.9 Severity Cut-Offs for Ordered Set of Optimal Dimensional Short-Forms Identified for 
Alcohol, Cannabis and Opioids (criteria used for each substance in Table 3.8) 
𝒑 Alcohol Cannabis Opioids 
 None Mild Mod Severe None Mild Mod Severe None Mild Mod Severe 
11 0 1-3 4-6 7-11 0 1 2-6 7-11 0 1-5 6-9 10-11 
10 0 1-2 3-5 6-10 0 1 2-5 6-10 0 1-4 5-8 9-10 
9 0 1-2 3-5 6-9 0 1 2-4 5-9 0 1-3 4-7 8-9 
8 0 1-2 3-5 6-8 0 1 2-3 4-8 0 1-3 4-6 7-8 
7 0 1-2 3-5 6-7 0 1 2-3 4-7 0 1-3 4-6 7 
6 0 1-2 3-4 5-6 0 1 2-3 4-6 0 1 2-5 6 
5 0 1 2-3 4-5 0 1 2 3-5 0 1 2-3 4-5 
4 0 1 2-3 4 0 1 2 3-4 0 1 2-3 4 




    
Figure 3.5 Mean Difference in R-Squared Among Ordered Set of Optimal Dimensional Short-




    
Figure 3.6 Mean Difference in R-Squared Among Ordered Set of Optimal Dimensional Short-






    
Discussion and Future Work 
In 2007, a multidisciplinary team of experts was convened by the APA to form the DSM-5 
Substance-Related Disorders Work Group whose purpose was to identify strengths and 
weaknesses in the DSM-IV approach to substance use disorders and to recommend 
improvements for the DSM-5 [Hasin et al., 2013].  One of the major improvements made in the 
transition from DSM-IV to DSM-5 for SUDs dealt with the merging of two distinct diagnoses 
for abuse and dependence (in DSM-IV) into one substance use disorder measured by 11 criteria 
(in DSM-5).  The Work Group’s extensive effort to improve the DSM also prompted new 
questions to be explored once DSM-5 was released in 2013.  Specifically, the Work Group stated 
the following in their 2013 report entitled “DSM-5 Criteria for Substance Use Disorders: 
Recommendations and Rationale”: “Implementing the 11 DSM-5 substance use disorders criteria 
in research and clinical assessment should be easier than implementing the 11 DSM-IV criteria 
for substance abuse and dependence, since now only one disorder is involved instead of two 
hierarchical disorders.  A checklist can aid in covering all criteria.  Eventually, reducing the 
number of criteria to diagnose substance use disorders will further aid implementation, which 
future studies should address.” [Hasin et al., 2013].  This last statement was the primary catalyst 
for our methodological development in the first Chapter.  We wanted to investigate whether we 
could develop a methodology to reduce the number of criteria while maintaining the same 
diagnostic ability as when using all 11 criteria.  In addition, with the changing paradigm for 
DSM revisions to be made more incrementally, we wanted to package the entire algorithm into a 




    
In our application to AUD, CUD and OUD, we found that excluding “Neglected major 
roles to use” (C5) and/or “Activities given up to use” (C7) and using a threshold of two, created 
no marked change in ability of these diagnostic short-forms to diagnose disorder (i.e., specificity 
= 1.00, sensitivity ≥ 0.985).  However, there are drawbacks to this brute-force method, especially 
dealing with run-time.  With 11 criteria, there are 2,047 different combinations of short-forms 
possible and when we increase this by just one criterion (i.e., 12), the number of combinations 
doubles (4,095).  While our method can easily deal with 12 criteria, we cannot dismiss the fact 
that the larger the criteria set is (e.g., 20+ criteria), the longer our algorithm will take.  Currently, 
the total run-time in SAS 9.4 for AUD with over 22,000 participants is 6 minutes while run-time 
for CUD (𝑛 = 3,701) and OUD (𝑛 = 1,579) is about 2-3 minutes each. 
 Our work in constructing an algorithm to identify diagnostic short-forms that act as 
similar as possible to the current DSM rule relied on the fact that the current rule was, in fact 
valid.  Hence in our second methodology, we wanted to propose a way to systematically identify 
short-forms that were as valid, or perhaps even more valid, than the current DSM.  However, the 
lack of an objective gold standard other than the DSM itself for psychiatric disorder diagnosis 
complicates validity testing.  A common strategy for assessing validity in the absence of a gold 
standard is to show that a diagnosis is associated with antecedent, concurrent and predictive 
validators.  Using this approach, we thought to compare the short-forms to each validator 
separately but we quickly found that there were issues with consensus for criteria 
included/excluded and threshold chosen across the different validators.  This led us to 
conceptualize a single summary measure for the external validators (i.e., ECV) and use that as 
our target for validation.  With the recent push for a severity diagnosis rather than a binary 
yes/no diagnosis, we utilized the severity categories of None, Mild, Moderate and Severe from 
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DSM-5 SUDs to create the framework for all possible dimensional short-forms.  The method 
developed constructs the dimensional short-forms using the three severity cut-offs (Mild, 
Moderate, Severe) in all possible locations within the subscale and currently does not allow for 
flexibility in the total number of severity groups.  In future work, we can extend the algorithm to 
allow for more severity groups (or less) to be assessed. 
 Using all 11 criteria, the data-driven validation method found that shifting the severity 
cut-offs to None (0 criteria), Mild (1-3 criteria), Moderate (4-6 criteria) and Severe (7-11 criteria) 
maximally discriminated ECV better than the current DSM-5 cut-offs for AUD.  For cannabis 
and opioid use disorder severity, the optimally valid cut-offs also involved a cut between 0 
(None) and 1 (Mild) although the split from Mild to Moderate and Moderate to Severe were 
different for cannabis (1 Mild, 2-6 Moderate, 7-11 Severe) and opioids (1-5 Mild, 6-9 Moderate, 
10-11 Severe).  These differential cut-offs for the different drugs suggest potentially different 
thresholds of importance of the criteria for causing functionality and impairment. 
  Among the most empirically valid dimensional short-forms identified for each of the 
three substances of size 𝑝 ≥ 5, each maintained at least one criterion from each of the four 
conceptual domains (Impaired Control, Social Impairment, Risky Use and Pharmacological).  
Moreover, dropping up to four criteria: “Used larger amounts/longer” (C1), “Repeated attempts 
to quit/control” (C2), “Activities given up to use” (C7) and “Hazardous use” (C8) led to even 
better external validity than using all 11 criteria.  The most valid 𝑝 = 6 rule for each of the three 
substance disorders keeps “Craving” (C4), “Social/interpersonal problems (C6), “Tolerance” 
(C10) indicating their central role to the disorders.  From the Risky Use domain, 
“Physical/psychological problems” (C9) is retained for alcohol and opioids, and “Hazardous use” 
(C8) is kept for cannabis and also opioids.  Also, of note, “Much time spent using” (C3) is the 
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final Impaired Control criterion kept for cannabis while it is not kept for either alcohol nor 
opioids. 
 While there are many similarities found across the substances, the most valid dimensional 
short forms are not exactly the same, hence there is some evidence to argue against the idea that 
the same short-forms (i.e., criteria included and severity cut-offs) should be used across all 
substances.  However, having different rules for different substances may not align with the 
original goal of the methodological development which was to reduce the number of criteria 
across all substances to make implementation easier.  One idea for future work that would 
attempt to address the concern of having different optimal short-forms for different substances 
would be to optimize across substances rather than within each substance.  In our demonstration 
for AUD, CUD and OUD, we would propose the use of a trivariate outcome and find the best 
short-form for all three substances rather than best for each substance.  This could mitigate the 
concern in identifying unique short-forms across each substance and find optimality over all 
substances.  Additionally, for the substances that did meet the minimum sample size 
requirements (e.g., heroin use disorder, cocaine use disorder) we suggest for future work to fit 
our methodologies to all of these substances combined (agnostic of disorder).  Since the current 
DSM approach requires the same rules apply for all substances, we feel that this approach could 
be justified. 
 Balancing clinical utility, reliability and validity are all important for the DSM.  While 
we address clinical utility in attempting to identify simpler criteria sets and validity in identifying 
simpler yet more externally valid criteria sets, we do not directly address reliability within the 
methodologies.  We recognize the importance of reliability and the need to assess reproducibility 
among measurements, especially when a new measurement tool is proposed.  Ideally, we would 
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do a reliability study of the new diagnostic short-form proposed by implementing a test-retest 
design where the criteria would be administered to the same participants and we would assess 
reliability across the two administrations.  Future work may also examine the short-form within 
the context of existing test-retest studies that asked the full set of criteria though one limitation is 
always that participants may respond differently when asked a smaller number of criteria 
compared to their original assessment.  Regardless, future work should also incorporate 
reliability testing and ideally it would be included within the method itself. 
 Inclusion of this additional reliability step could help with another problem we 
encountered in our methodology for identifying and validating dimensional short-forms.  We 
were having difficulty in narrowing down ‘the best’ dimensional short-forms once 𝑅2 was 
estimated and the top performers were identified.  This was one of the reasons we added in the 
ordered severity property where a severity categorization cannot be more severe in a dimensional 
short-form with less criteria.  The ‘property’ makes sense when presenting the final list of 
dimensional short-forms for each size of 𝑝.  However, if the goal was to find the overall best rule 
regardless of 𝑝, then more investigation needs to be done to establish this as there was no 
statistical difference in 𝑅2 between the top performing dimensional short-form and the next best, 
driven mainly by the slight variations in severity groups.  For example, one of the top performing 
𝑝 = 9 dimensional short-forms had 𝑟2 = 0.1915 (95% CIs: 0.1795, 0.2034) with the following 
severity cut-offs: None (0 criteria), Mild (1-2 criteria), Moderate (3-4 criteria) and Severe (5-9 
criteria).  Another 𝑝 = 9 top performer had 𝑟2 = 0.1909 (95% CIs: 0.1791, 0.2027) but had a 
slight change in the Moderate (3-5 criteria) and Severe (6-9 criteria) categories.  It would be 
useful to find a way to investigate the differences even further within these and apply it to all 
dimensional short-forms to help narrow down the “best” dimensional short-forms overall.   
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The present methodology relies on having a starting set of criteria endorsed by a subject.  
Whether a criterion is endorsed or not depends on many things that may lead to possible 
systematic measurement error including, e.g. how the items are worded, the question order, and 
the interaction with the rater.  Future work could extend the method to incorporate continuous 
and high-dimensional biological and imaging markers as they become available.  As the valid 
measurement of psychiatric and substance use disorders improves, so will our understanding of 





Appendix A: Survey Questions from NESARC-III Used to Elicit Each Criterion for Alcohol 


















































Appendix B: Survey Questions from Wave 2 NESARC Used to Elicit Each Criterion for 
Alcohol 
 


















































































Appendix C: Survey Questions from NESARC-III Used to Elicit Each Criterion (C1 to C10) for 
Cannabis/Opioids 
 
























Appendix D: Survey Questions from NESARC-III Used to Elicit the Withdrawal (C11) 
Criterion for Cannabis and Opioids 
 























Symptom 1 ≥ 1 
(22) Become more irritable than usual? 
(24) Feel angry, combative or aggressive (when 
the effects of a medicine or drug are wearing 
off)? 
Symptom 2 = 1 (11) Feel anxious or nervous? 
Symptom 3 ≥ 1 
(17) Have unpleasant drams that often seemed 
real? 
(20) Have trouble falling asleep or staying 
asleep? 
Symptom 4 = 1 (23) Eat less than usual or lose weight? 
Symptom 5 = 1 
(14) Become so restless you fidgeted, paced or 
couldn’t sit still? 
Symptom 6 = 1 (5) Feel depressed? 
Symptom 7 ≥ 1 
(13) Have a fever? 
(19) Feel shaky or have shaky or trembling 
hands? 
(25) Have a headache? 
(26) Find yourself sweating? 
(27) Have chills (when the effects of a medicine 
or drug were wearing off)? 
(28) Have stomach pain? 
Withdrawal 
Item B = 1 
Symptom 1 = 1 
(29) Table more of the same or a similar 
medicine or drug to get over or avoid any of 



























Symptom 1 = 1 (5) Feel depressed? 
Symptom 2 = 1 (7) Have nausea or vomiting? 
Symptom 3 = 1 
(12) Have muscle aches or cramps (when the 
effects of a medicine or drug were wearing off)? 
Symptom 4 = 1 
(9) Have runny eyes or a runny nose (when the 
effects of a medicine or drug were wearing off)? 
Symptom 5 = 1 
(16) Find your pupils dilating or your hair 
standing up? 
Symptom 6 = 1 (28) Have stomach pain? 
Symptom 7 = 1 (8) Yawn a lot? 
Symptom 8 = 1 (13) Have a fever? 
Symptom 9 = 1 
(20) Have trouble falling asleep or staying 
asleep? 
Withdrawal 
Item B = 1 
Symptom 1 = 1 
(29) Table more of the same or a similar 
medicine or drug to get over or avoid any of 




Appendix E: %DSFv2: A Flexible SAS® Macro That Identifies Diagnostic Short-Forms 
 
Introduction 
Lengthy criteria sets can be problematic and provide the primary motivation to identify short-
forms.  This paper explores how custom SAS macro, %DSFv2, can be used to systematically 
identify subsets and associated cut-offs that yield diagnoses as similar as possible to using the 
original full-length criteria set.  Using DSM-5 alcohol use disorder (AUD) as our example with 
11 diagnostic criteria and the current rule of 2+ criteria endorsed for an AUD diagnosis, the 
macro identifies diagnostic short-forms by: (1) maximizing the association between the sum 
scores of all 11 criteria with newly constructed subscales from subsets of criteria, (2) optimizing 
the similarity of AUD prevalence between the current DSM-5 rule and newly constructed 
diagnostic short-forms, (3) maximizing sensitivity and specificity of the short-forms against the 
current DSM-5 rule, and (4) minimizing differences in the accuracy of the short-form across 
chosen covariates.  At the end of the macro, a final list of optimal diagnostic short-form 




[file=, dsn=, criteriavars=, dxvar=] 
The first 4 macro calls (file=, dsn=, criteriavars=, dxvar=) are all REQUIRED and the first two 
identify the file location on your computer (file=) where the users dataset is found (dsn=).  Then, 
you must list out the names of the criteria with a single space in between (criteriavars=var1 var2) 
and identify the name of the current diagnostic rule (dxvar=).  If the data has a weight variable 









The example below provides the file location of the nesarc3.sas7bdat dataset with the list of 11 
diagnostic criteria used for the diagnosis of AUD.  Also, the variable name for the current rule to 








The rest of the macro call mimic the steps as outlined in the introduction (i.e., correlation step, 
prevalence step).  The first macro call (DataPrep=No) needs to be switch on (DataPrep=Yes) to 
create bootstrap data off of the dataset (&dsn) provided by the user.  The default has 50 bootstrap 
samples (bsamp=50) but can be adjusted depending on the user. 
 
When there are 11 criteria, there are 2,047 possible subscales that can be constructed of size p=1 
to 11.  Below provides an example of the bootstrapped data (BootSamp=1 to 50) with variables 


















The next macro call (Corr=No) needs to be switched on (Corr=Yes) for the first screening step of 
the algorithm to run.  This uses the bootstrapped data created previously and creates all possible 
combinations of subsets of criteria, obtains sum scores for each subset to create subscales and 
correlates each subscale with the current diagnosis (as specified with dxvar=).  Once all 
estimates of correlation are calculated, 95% confidence intervals are estimated and for each size 
of subscale (p=1, 2, ... total number of criteria), the top ranked subscale and any not significantly 
different are selected to move to the next step. 
 
Below provides an example of the selection of subscales with six criteria included (p=6).  This 
step takes the top subscale for size p=6 and any not significantly different.  Among the 462 


























This macro call is the second screening step in the algorithm.  It takes the optimal subscales 
selected in the previous section and incorporates the threshold component for diagnosing 
disorder.  Specifically, for each size of the subscale (p), we let the threshold (m) vary across all 
possible sizes.  If there are four criteria included in a subscale (p=4), then four diagnostic short-
forms can be constructed where the threshold ranges from m=1 to 4.  For the first diagnostic 
short-form, only 1 criterion needs to be endorsed for a diagnosis made but for the last one, all 
four criteria must be endorsed for a diagnosis.  This is extrapolated to all subscales.  Once all 
possible diagnostic short-forms are constructed, the prevalence of disorder is estimated in the 
sample and those that are within a percentage of the current rule prevalence are selected to move 
to the next step.  The percentage difference is set at 5% (default) but can be adjusted depending 
on the user. 
 
The figure below provides the difference in prevalence between DSM-5 AUD and diagnostic 
short-forms where values greater than zero indicate DSF prevalence is higher than DSM-5 AUD 
prevalence and values less than zero indicate DSF prevalence is lower than DSM-5 AUD.  Those 





















This is the second to last screening step and uses the current rule (dxvar=) to estimate sensitivity 
and specificity for each diagnostic short-form.  The user can set the threshold for the diagnostic 
short-forms that make it to the next step (diagacc=) which is currently set to only take those that 
have Sensitivity/Specificity estimates (and 95% confidence intervals) ≥ 0.90. 
 
The figure below provides the sensitivity vs. 1-specificity and 95% confidence intervals around 
sensitivity among the diagnostic short-forms that made it to this screening step.  The ones that 
fall above the threshold set (diagacc=0.90) move to the last step.  In this example, the red 
























The last screening step, requires the user to impute the variable names of the covariates used to 
assess differential test functioning (DTF) for each of the remaining diagnostic short-forms.  That 
is, it should not exhibit systematic differences in the way it measures the target construct in 
different subgroups than what is currently being captured by the full-length rule.  In our setting, 
we are concerned with reducing the systematic differences with the entire diagnostic short-form 
rather than with each item within the short-form. 
 
In our example, we assess whether the diagnostic short-forms that made it through all the 
previous steps have any differential functioning by the covariates listed (covars=).  However, 
currently the macro can only handle binary covariates. 
 
At the end of the algorithm, a final list of optimal diagnostic short-forms are provided.  Each step 
in the process creates a new dataset saved to your file location which are called upon in the tables 
























Example of Tables & Figures produced by macro: 
Criteria Included/Excluded in the 8 Optimal Diagnostic Short-forms for DSM-5 AUD* - Step 8 
 






Prevalence1 Sensitivity Specificity 
74 10 2 0.998 (0.998, 0.998) 0.191 (0.185, 0.196) 0.998 (0.997, 0.999) 1.000 (1.000, 1.000) 
26 10 2 0.998 (0.998, 0.998) 0.191 (0.185, 0.196) 0.998 (0.997, 1.000) 1.000 (1.000, 1.000) 
89 9 2 0.995 (0.994, 0.995) 0.190 (0.185, 0.196) 0.996 (0.995, 0.998) 1.000 (1.000, 1.000) 
344 8 2 0.988 (0.987, 0.988) 0.188 (0.183, 0.194) 0.986 (0.982, 0.990) 1.000 (1.000, 1.000) 
120 8 2 0.987 (0.987, 0.988) 0.184 (0.178, 0.190) 0.964 (0.957, 0.970) 1.000 (1.000, 1.000) 
375 7 2 0.978 (0.977, 0.979) 0.182 (0.176, 0.188) 0.953 (0.946, 0.960) 1.000 (1.000, 1.000) 
988 4 1 0.922 (0.919, 0.925) 0.213 (0.207, 0.218) 0.898 (0.887, 0.908) 0.949 (0.945, 0.953) 









Developer: Cheri Raffo 
Location: Brooklyn, NY 
Date: March 2018 
 
There are two macros available for download: 
(1) %DSF_v2  
a. This macro runs through each step as described in this article and provides a final 
dataset with the optimal diagnostic short-forms for the specified data set. 
(2) %DSFTF_v2 
a. This macro uses the datasets created in the previous macro to output tables and 
figures used to investigate findings 
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